Report Sections

See All Reports

Coronavirus Infections (722) Severe Acute Respiratory Syndrome (493) Infection (402) Pneumonia (331) Communicable Diseases (176) Respiratory Distress Syndrome, Adult (161) Acute Lung Injury (126) Respiratory Distress Syndrome, Newborn (126) (114) Syndrome (106) Virus Diseases (85) Pneumonia, Viral (73) Critical Illness (63) Depression (62) Anxiety Disorders (44) Disease (39) Stress Disorders, Post-Traumatic (34) Emergencies (31) Respiratory Tract Infections (31) Inflammation (30) Neoplasms (30) Cardiovascular Diseases (29) Stress Disorders, Traumatic (29) Wounds and Injuries (29) Lung Injury (27) Stress, Psychological (27) Mental Disorders (26) Diabetes Mellitus (25) Hypoxia (25) Depressive Disorder (24) Thrombosis (23) Hypertension (22) Respiratory Tract Diseases (22) Acute Kidney Injury (21) Lung Diseases (21) Disease Progression (18) Olfaction Disorders (18) Embolism (16) Influenza, Human (16) Stroke (16) Arthritis (15) Pulmonary Embolism (15) Respiration Disorders (15) Blood Coagulation Disorders (14) HIV Infections (14) Hemostatic Disorders (14) Thromboembolism (14) Burnout, Psychological (13) Chronic Disease (13) Fibrosis (13) Lung Diseases, Obstructive (13) Multiple Sclerosis (13) Sclerosis (13) Cognitive Dysfunction (12) Diabetes Mellitus, Type 2 (12) Lung Diseases, Interstitial (12) Myocardial Infarction (12) Pulmonary Disease, Chronic Obstructive (12) Pulmonary Fibrosis (12) Respiratory Aspiration (12) Arthritis, Rheumatoid (11) Autism Spectrum Disorder (11) Brain Injuries (11) Chronic Pain (11) Heart Diseases (11) Kidney Diseases (11) Substance-Related Disorders (11) Venous Thrombosis (11) Crohn Disease (10) Diabetes Mellitus, Type 1 (10) Heart Failure (10) Infarction (10) Lung Neoplasms (10) Autistic Disorder (9) Dyspnea (9) Myocarditis (9) Obesity (9) Pneumonia, Ventilator-Associated (9) Pregnancy Complications (9) Brain Injuries, Traumatic (8) Carcinoma (8) Colitis (8) Colitis, Ulcerative (8) Depression, Postpartum (8) Liver Diseases (8) Renal Insufficiency, Chronic (8) Respiratory Syncytial Virus Infections (8) Rheumatic Diseases (8) Ulcer (8) Vitamin D Deficiency (8) Coronary Artery Disease (7) Coronary Disease (7) Dementia (7) Feeding and Eating Disorders (7) Hematologic Neoplasms (7) Infertility (7) Inflammatory Bowel Diseases (7) Kidney Failure, Chronic (7) Parkinson Disease (7) Problem Behavior (7) Pulmonary Valve Insufficiency (7) Venous Thromboembolism (7) Burnout, Professional (6) Collagen Diseases (6) Frailty (6) Immune System Diseases (6) Immunologic Deficiency Syndromes (6) Ischemia (6) Lupus Erythematosus, Systemic (6) Lymphoma (6) Musculoskeletal Pain (6) Overweight (6) Parasomnias (6) Pediatric Obesity (6) Psychotic Disorders (6) RNA Virus Infections (6) Sepsis (6) Shock (6) Spinal Cord Injuries (6) Acute Coronary Syndrome (5) Alcohol Drinking (5) Alcoholism (5) Autoimmune Diseases (5) Breast Neoplasms (5) Carcinoma, Non-Small-Cell Lung (5) Child Development Disorders, Pervasive (5) Convalescence (5) Coronaviridae Infections (5) Cystic Fibrosis (5) Delirium (5) Depressive Disorder, Major (5) Disease Susceptibility (5) Dyssomnias (5) Gastroparesis (5) Hypersensitivity (5) Leukemia (5) Lymphopenia (5) Multiple Organ Failure (5) Myocardial Ischemia (5) Neurologic Manifestations (5) Osteoarthritis (5) Prostatic Neoplasms (5) Renal Insufficiency (5) Alzheimer Disease (4) Asthma (4) Attention Deficit Disorder with Hyperactivity (4) Behavior, Addictive (4) Body Weight (4) Brain Diseases (4) Coinfection (4) Colonic Neoplasms (4) Death (4) Deglutition Disorders (4) Disseminated Intravascular Coagulation (4) Embolism and Thrombosis (4) Fibromyalgia (4) Head and Neck Neoplasms (4) Heart Arrest (4) Hemorrhage (4) Hypertension, Pulmonary (4) Liver Cirrhosis (4) Metabolic Syndrome (4) Migraine Disorders (4) Mycobacterium Infections (4) Neoplasm Metastasis (4) (4) Pancreatic Neoplasms (4) Postoperative Complications (4) Prediabetic State (4) Signs and Symptoms, Respiratory (4) Sjogren's Syndrome (4) Sleep Apnea Syndromes (4) Sleep Initiation and Maintenance Disorders (4) Thrombophilia (4) Vascular Diseases (4) Weight Loss (4) Acquired Immunodeficiency Syndrome (3) Adenoviridae Infections (3) Appendicitis (3) Arrhythmias, Cardiac (3) Arthritis, Psoriatic (3) Asymptomatic Diseases (3) Bronchiectasis (3) Carcinoma, Renal Cell (3) Cardiomyopathies (3) Chilblains (3) Common Cold (3) Cross Infection (3) Dermatitis (3) Developmental Disabilities (3) Digestive System Diseases (3) Dysgeusia (3) Endometriosis (3) Fatigue (3) Fever (3) Gastrointestinal Diseases (3) Giant Cell Arteritis (3) Glucose Intolerance (3) Glucose Metabolism Disorders (3) Hemophilia A (3) Leukemia, Lymphoid (3) Macular Edema (3) Malnutrition (3) Measles (3) Melanoma (3) Metabolic Diseases (3) Mucocutaneous Lymph Node Syndrome (3) (3) Nervous System Diseases (3) Neuroendocrine Tumors (3) Occupational Stress (3) Osteoarthritis, Knee (3) Ovarian Neoplasms (3) Panic Disorder (3) Paramyxoviridae Infections (3) Peripheral Arterial Disease (3) Polymyalgia Rheumatica (3) Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) Pregnancy Complications, Infectious (3) Premature Birth (3) Psychological Trauma (3) Pulmonary Edema (3) Rheumatic Fever (3) ST Elevation Myocardial Infarction (3) Schizophrenia (3) Seizures (3) Sleep Apnea, Obstructive (3) Sleep Wake Disorders (3) Systemic Inflammatory Response Syndrome (3) Taste Disorders (3) Tobacco Use Disorder (3) Triple Negative Breast Neoplasms (3) Ventricular Dysfunction (3) Ventricular Dysfunction, Left (3) Acute Disease (2) Ageusia (2) Agoraphobia (2) Alopecia (2) Alpha 1-Antitrypsin Deficiency (2) Amyotrophic Lateral Sclerosis (2) Anemia, Sickle Cell (2) Angina Pectoris (2) Angioedema (2) Angioedemas, Hereditary (2) Anxiety, Separation (2) Arteritis (2) Asymptomatic Infections (2) Atherosclerosis (2) Atrial Fibrillation (2) Bacterial Infections (2) Behcet Syndrome (2) Bipolar Disorder (2) Caliciviridae Infections (2) Clinical Deterioration (2) Cognition Disorders (2) Colorectal Neoplasms (2) Communicable Diseases, Emerging (2) Compassion Fatigue (2) Compulsive Personality Disorder (2) Congenital Abnormalities (2) Conjunctivitis (2) Dermatitis, Atopic (2) Diarrhea (2) Drug-Related Side Effects and Adverse Reactions (2) Eczema (2) Emphysema (2) Endocrine System Diseases (2) Fatigue Syndrome, Chronic (2) Ganglion Cysts (2) Gastroenteritis (2) Gastroesophageal Reflux (2) Gaucher Disease (2) Glioblastoma (2) Headache (2) Healthcare-Associated Pneumonia (2) Heart Defects, Congenital (2) Heart Failure, Systolic (2) Hematologic Diseases (2) Huntington Disease (2) Hyperglycemia (2) Hyperkinesis (2) Hyperphagia (2) Hypothermia (2) Hypoventilation (2) Idiopathic Pulmonary Fibrosis (2) Intervertebral Disc Degeneration (2) Intestinal Diseases (2) Ischemic Attack, Transient (2) Jaundice (2) Leukemia, Myeloid, Acute (2) Lymphoproliferative Disorders (2) Macular Degeneration (2) Mobility Limitation (2) Mood Disorders (2) Motor Neuron Disease (2) Multiple Myeloma (2) Multiple Sclerosis, Relapsing-Remitting (2) Muscular Dystrophies (2) Mutism (2) Mycoses (2) Myelodysplastic Syndromes (2) Myeloproliferative Disorders (2) Myositis (2) Necrosis (2) Neoplasms, Plasma Cell (2) Nerve Degeneration (2) Neurodevelopmental Disorders (2) Nidovirales Infections (2) Noncommunicable Diseases (2) Nutrition Disorders (2) Obesity, Morbid (2) Obsessive-Compulsive Disorder (2) Oral Manifestations (2) Pain, Postoperative (2) Peripheral Vascular Diseases (2) Phobia, Social (2) Phobic Disorders (2) Pneumonia, Pneumocystis (2) Psoriasis (2) Purpura, Thrombocytopenic, Idiopathic (2) Rare Diseases (2) Recurrence (2) Respiratory Sounds (2) Sarcoidosis (2) Shock, Septic (2) Small Cell Lung Carcinoma (2) Spinal Diseases (2) Sprains and Strains (2) Suicidal Ideation (2) Suicide (2) Tachycardia (2) Thoracic Diseases (2) Thrombocytopenia (2) Toxemia (2) Trauma and Stressor Related Disorders (2) Tuberculosis (2) Urinary Bladder, Overactive (2) Urinary Tract Infections (2) Uterine Cervical Neoplasms (2) Uveitis (2) Vision Disorders (2) Vision, Low (2) Yellow Fever (2) Abruptio Placentae (1) Acalculous Cholecystitis (1) Adenocarcinoma (1) Adjustment Disorders (1) Adrenal Insufficiency (1) Alcohol Drinking in College (1) Alcohol-Related Disorders (1) Alcoholic Intoxication (1) Alveolitis, Extrinsic Allergic (1) Amblyopia (1) Anemia, Aplastic (1) Angina, Stable (1) Anorexia (1) Anorexia Nervosa (1) Aortic Valve Stenosis (1) Apnea (1) Arthritis, Juvenile (1) Aspergillosis (1) Aspergillosis, Allergic Bronchopulmonary (1) Asphyxia Neonatorum (1) Asthenopia (1) Atrioventricular Block (1) Atrophy (1) Autonomic Nervous System Diseases (1) Back Pain (1) Bacteremia (1) Barotrauma (1) Birth Weight (1) Blister (1) Body Weight Changes (1) Bone Diseases, Metabolic (1) Bradycardia (1) Brain Concussion (1) Breast Cancer Lymphedema (1) Bronchial Diseases (1) Bronchiolitis (1) Bronchitis (1) Bronchitis, Chronic (1) Bronchopulmonary Dysplasia (1) Brucellosis (1) Bulimia (1) Calculi (1) Carcinoma, Hepatocellular (1) Carcinoma, Ovarian Epithelial (1) Carcinoma, Small Cell (1) Carcinoma, Squamous Cell (1) Cardiovascular Abnormalities (1) Cataract (1) Celiac Disease (1) Cellulitis (1) Cerebral Hemorrhage (1) Cerebral Palsy (1) Cerebrovascular Disorders (1) Chest Pain (1) Chlamydia Infections (1) Cholangiocarcinoma (1) Cholangitis (1) Cholecystitis (1) Cholecystitis, Acute (1) Chronic Traumatic Encephalopathy (1) Clostridium Infections (1) (1) Colonic Diseases (1) Communication Disorders (1) Compulsive Behavior (1) Consciousness Disorders (1) Constipation (1) Constriction, Pathologic (1) Conversion Disorder (1) (1) (1) Coronary Artery (1) Coronary Stenosis (1) (1) Cough (1) Coxsackievirus Infections (1) Cryopyrin-Associated Periodic Syndromes (1) Deafness (1) Death, Sudden, Cardiac (1) Dental Calculus (1) Dental Plaque (1) Depressi (1) Depressive Disorder, Treatment-Resistant (1) DiGeorge Syndrome (1) Diabetic Nephropathies (1) Diabetic Neuropathies (1) Diphtheria (1) (1) Down Syndrome (1) Dyspareunia (1) Emergence Delirium (1) Encephalitis (1) Endocarditis (1) Endophthalmitis (1) Endotoxemia (1) Enuresis (1) Epilepsy (1) Esophageal and Gastric Varices (1) Esophagitis, Peptic (1) Eye Diseases (1) Eye Infections (1) Fabry Disease (1) Facial Pain (1) Familial Mediterranean Fever (1) Fatty Liver (1) (1) Femoral Neck Fractures (1) Fetal Growth Retardation (1) Fetal Membranes, Premature Rupture (1) Fever of Unknown Origin (1) Fistula (1) Food Hypersensitivity (1) Fractures, Closed (1) Fractures, Stress (1) Gait Disorders, Neurologic (1) Genetic Diseases, Inborn (1) Genetic Predisposition to Disease (1) Gestational Weight Gain (1) Gingivitis, Necrotizing Ulcerative (1) Gout (1) (1) Headache Disorders, Secondary (1) Hearing Loss (1) Hearing Loss, Conductive (1) Heart Failure, Diastolic (1) Heart Murmurs (1) Helminthiasis (1) Hematoma (1) Hematoma, Subdural (1) Hematoma, Subdural, Chronic (1) Hemoglobinopathies (1) Hepatitis (1) Hepatitis A (1) Hepatitis C (1) Hepatitis, Alcoholic (1) Hereditary Autoinflammatory Diseases (1) Herpes Labialis (1) Herpes Zoster (1) Hodgkin Disease (1) Hyaline Membrane Disease (1) Hyperaldosteronism (1) Hypercapnia (1) Hyperphosphatemia (1) Hyperplasia (1) Hypersensitivity, Immediate (1) Hypertension, Pregnancy-Induced (1) Hypokalemia (1) Hyponatremia (1) Hypoparathyroidism (1) Hypotension (1) Iatrogenic Disease (1) Infant, Newborn, Diseases (1) Infec (1) Infecti (1) Infertility, Female (1) Infertility, Male (1) Intellectual Disability (1) Intestinal Atresia (1) Intracranial Hypertension (1) Intracranial Thrombosis (1) Jaundice, Obstructive (1) Joint Diseases (1) Keratoconjunctivitis (1) Keratosis (1) Keratosis, Actinic (1) Leishmaniasis (1) Leukemia, Lymphocytic, Chronic, B-Cell (1) Leukemia, Myeloid (1) Leukemia, Myelomonocytic, Acute (1) Leukemia, Myelomonocytic, Chronic (1) Liver Cirrhosis, Biliary (1) Liver Failure (1) Low Back Pain (1) Lung (1) Lyme Disease (1) Lymphedema (1) Lymphocytosis (1) Lymphoma, B-Cell (1) Lymphoma, Mantle-Cell (1) Macrophage Activation Syndrome (1) Malaria (1) Maternal Death (1) Maxillofacial Injuries (1) Memory Disorders (1) Meningitis (1) Meningitis, Meningococcal (1) Menorrhagia (1) Menstruation Disturbances (1) Microvascular Rarefaction (1) Mitochondrial Diseases (1) Molluscum Contagiosum (1) Monoclonal Gammopathy of Undetermined Significance (1) Mouth Diseases (1) Mouth, Edentulous (1) Movement Disorders (1) Mucositis (1) Multiple Chronic Conditions (1) Muscle Spasticity (1) Muscular Atrophy (1) Muscular Dystrophy, Duchenne (1) Myalgia (1) Myocardial Reperfusion Injury (1) Myofascial Pain Syndromes (1) Needlestick Injuries (1) Neonatal Sepsis (1) Neoplastic Cells, Circulating (1) Nephritis (1) Neurobehavioral Manifestations (1) Neurocognitive Disorders (1) Neuromyelitis Optica (1) Non-alcoholic Fatty Liver Disease (1) Obsessive Behavior (1) Olfactory Nerve Injuries (1) Orbital Cellulitis (1) Osteoarthritis, Hip (1) Osteochondritis (1) Osteomyelitis (1) Otitis Media with Effusion (1) Overweig (1) Pain (1) Pain, Procedural (1) Pancreatitis (1) Paraproteinemias (1) Paresis (1) Peanut Hypersensitivity (1) Perinatal Death (1) Periodontal Diseases (1) Peripheral Nervous System Diseases (1) Peritoneal Neoplasms (1) Pharyngeal Diseases (1) Pleuropneumonia (1) (1) (1) Pneumonia, Bacterial (1) Pneumonia, V (1) Pre-Eclampsia (1) Pregnancy in Diabetics (1) Preleukemia (1) Primary Dysautonomias (1) Prostatic Hyperplasia (1) Protein-Energy Malnutrition (1) Psychophysiologic Disorders (1) Puerperal Infection (1) Pulmonary Alveolar Proteinosis (1) Pulmonary Aspergillosis (1) Pulmonary Atelectasis (1) Pulmonary Eosinophilia (1) Radiculopathy (1) Rectal Neoplasms (1) Reperfusion Injury (1) (1) (1) Respiratory Distress Sy (1) Respiratory Hypersensitivity (1) Retinal Vein Occlusion (1) Rupture (1) Sarcoidosis, Pulmonary (1) Sarcopenia (1) Schizophrenia Spectrum and Other Psychotic Disorders (1) (1) Scleroderma, Localized (1) Scleroderma, Systemic (1) Self-Injurious Behavior (1) Severe Acute Respiratory Syn (1) Sexually Transmitted Diseases (1) Sexually Transmitted Diseases, Bacterial (1) Shock, Cardiogenic (1) Short Bowel Syndrome (1) Signs and Symptoms, Digestive (1) Skin Abnormalities (1) Skin Diseases (1) Skin Manifestations (1) Skin Neoplasms (1) Skull Fractures (1) Sleep Apnea, Central (1) Soft Tissue Neoplasms (1) Somatoform Disorders (1) Spinal Stenosis (1) Spondylarthritis (1) Spondylolisthesis (1) Status Epilepticus (1) Stillbirth (1) Stomatitis (1) Str (1) Stress Disorders, Traumatic, Acute (1) Subarachnoid Hemorrhage (1) Superinfection (1) Syncope (1) Syncope, Vasovagal (1) Tachycardia, Sinus (1) Tachycardia, Ventricular (1) Temporomandibular Joint Disorders (1) Temporomandibular Joint Dy (1) Temporomandibular Joint Dysfunction Syndrome (1) Thalassemia (1) Thrombophlebitis (1) Torsades de Pointes (1) Tourette Syndrome (1) Trauma, Nervous System (1) Trichuriasis (1) Tuberculosis, Pulmonary (1) Ulce (1) Urinary Bladder, Underactive (1) Urinary Incontinence (1) Urinary Retention (1) Urologic Diseases (1) Urticaria (1) Uterine Neoplasms (1) Vaginal Neoplasms (1) Ventricular Dysfunction, Right (1) Virus Dis (1) Von Willebrand Diseases (1) Vulvar Neoplasms (1) Weight Gain (1) Xerostomia (1) beta-Thalassemia (1)

D007674: Kidney Diseases

Developed by Shray Alag, The Harker School
Sections: Correlations, Clinical Trials, and HPO

Correlations computed by analyzing all clinical trials.

Navigate: Clinical Trials and HPO


Correlated Drug Terms (15)


Name (Synonyms) Correlation
drug3639 Verinurad Wiki 0.52
drug213 Allopurinol Wiki 0.52
drug1243 Exercise training group Wiki 0.30
Name (Synonyms) Correlation
drug2732 Quantitative IgG Test Wiki 0.30
drug136 AZD5718 Wiki 0.30
drug1712 Intervention-EDI and health coaching Wiki 0.30
drug892 Control-EDI Wiki 0.30
drug936 Covid-19 Rapid Test Kit (RAPG-COV-019) Wiki 0.30
drug991 Dapagliflozin 10 mg Wiki 0.30
drug954 Cyclosporine Wiki 0.27
drug2894 Rifampicin Wiki 0.21
drug2460 Pentoxifylline Wiki 0.21
drug401 BI 764198 Wiki 0.21
drug2505 Placebo Wiki 0.04
drug1520 Hydroxychloroquine Wiki 0.03

Correlated MeSH Terms (9)


Name (Synonyms) Correlation
D051436 Renal Insufficiency, Chronic NIH 0.85
D003928 Diabetic Nephropathies NIH 0.30
D007676 Kidney Failure, Chronic NIH 0.23
Name (Synonyms) Correlation
D002908 Chronic Disease NIH 0.17
D051437 Renal Insufficiency, NIH 0.13
D007154 Immune System Diseases NIH 0.12
D006973 Hypertension NIH 0.06
D003141 Communicable Diseases NIH 0.02
D007239 Infection NIH 0.02

Correlated HPO Terms (4)


Name (Synonyms) Correlation
HP:0000077 Abnormality of the kidney HPO 0.90
HP:0012622 Chronic kidney disease HPO 0.74
HP:0000083 Renal insufficiency HPO 0.13
Name (Synonyms) Correlation
HP:0000822 Hypertension HPO 0.08

Clinical Trials

Navigate: Correlations   HPO

There are 11 clinical trials


1 CSP #2008 - Pentoxifylline in Diabetic Kidney Disease

Pentoxifylline (PTX) is a medication that has been on the market since 1984 for use in disease in the blood vessels of the legs. There is some preliminary information that it may protect the kidneys from damage due to diabetes and other diseases. "Pentoxifylline in Diabetic Kidney Disease" is a study to bee conducted in 40 VA hospitals across the nation to determine definitively whether or not PTX can prevent worsening of kidney disease and delay death in patients with diabetic kidney disease.

NCT03625648
Conditions
  1. Diabetic Kidney Disease
Interventions
  1. Drug: Pentoxifylline
  2. Drug: Placebo
MeSH:Kidney Diseases Diabetic Nephropathies
HPO:Abnormality of the kidney Nephropathy

Primary Outcomes

Description: ESRD will be defined as need for chronic dialysis or renal transplantation.

Measure: Time to ESRD or death

Time: 5 to 9 years

Secondary Outcomes

Description: Quality of life as measured by the Kidney Disease Quality of Life Short Form (KDQoL-SF)

Measure: Quality of life (KDQoL-SF)

Time: 5 to 9 years

Description: Time until doubling of serum creatinine

Measure: Time until doubling of serum creatinine

Time: 5 to 9 years

Description: The risk of a CHF hospitalization will be based on the participant-time data, specifically, the number of events per years.

Measure: Incidence of congestive heart failure hospitalization (CHF)

Time: 5 to 9 years

Description: The risk of a MACE event will be based on participant-time data, specifically, the number of events per participant years.

Measure: Incidence of a three-point MACE

Time: 5 to 9 years

Description: The risk of a PVD event will be based on participant-time data, specifically, the number of events per participant years.

Measure: Incidence of a peripheral vascular disease (PVD)

Time: 5 to 9 years

Description: Percentage of participants with 50% reduction in UACR from baseline

Measure: Percentage of participants with 50% reduction in UACR from baseline

Time: 5 to 9 years

Description: Rate of change in eGFR per year during the study period.

Measure: Rate of change in eGFR per year during the study period

Time: 5 to 9 years
2 Controlling Hypertension Through Education and Coaching in Kidney Disease

Chronic kidney disease (CKD) is a serious and growing public health problem. The purpose of this study is to find out if an educational worksheet, called the Encounter Decision Intervention (EDI), combined with health coaching helps CKD patients improve their blood pressure and other health outcomes. The research team hypothesizes that the intervention group will have greater improvement in CKD outcomes than the control group.

NCT04087798
Conditions
  1. Chronic Kidney Diseases
  2. Chronic Disease
  3. Chronic Kidney Disease, Stage 3 (Moderate)
  4. Chronic Kidney Disease, Stage 4 (Severe)
  5. Chronic Kidney Disease Stage 5
Interventions
  1. Behavioral: Control-EDI
  2. Behavioral: Intervention-EDI and health coaching
MeSH:Kidney Diseases Renal Insufficiency, Chronic Hypertension Chronic Disease
HPO:Abnormality of the kidney Chronic kidney disease Hypertension Nephropathy

Primary Outcomes

Description: Changes in systolic blood pressure between baseline and 12 months will be compared between the intervention group and control group.

Measure: Change in Systolic Blood Pressure between baseline and 12 months

Time: Baseline, 12 months

Secondary Outcomes

Description: Changes in diastolic blood pressure between baseline and 12 months will be compared between the intervention group and control group.

Measure: Change in Diastolic Blood Pressure between baseline and 12 months

Time: Baseline, 12 months

Description: BP will be collected at 4 time points - baseline, 1, 6, 12 months. This will be compared between the intervention group and control group.

Measure: Slope of systolic BP between baseline and 12 months using all available BP values

Time: Baseline up to 12 months

Description: BP will be collected at 4 time points - baseline, 1, 6, 12 months. This will be compared between the intervention group and control group.

Measure: Slope of diastolic BP between baseline and 12 months using all available BP values

Time: Baseline up to 12 months

Description: This is a 28-item questionnaire measuring objective CKD disease knowledge and includes questions about goals, cardiovascular risk, and anti-hypertensive medications. Patients will answer the questions with a yes or no answer and their score will be based on how many responses were correct. This number will be converted to a percentage.

Measure: CKD knowledge measured by the Kidney Knowledge Survey (KiKS)

Time: Baseline up to 12 months

Description: This is a 13-item measure with the answers on a Likert scale of 1 (not at all sure) to 4 (extremely sure). The higher the score the higher the self-efficacy, with a range from 13-52.

Measure: Medication Adherence Self-Efficacy Scale-Revised (MASES-R)

Time: Baseline up to 12 months

Description: This scale is to quantify adherence to pharmacological treatments by means of 8 items. Patients will answer yes or no to these items, where a no response = 1 point and a yes response = 0 points. Levels of adherence are based on the following scores: 3-8 = low adherence; 1-2 = medium adherence; 0 = high adherence.

Measure: Morisky Medication Adherence Scale (MMAS - 8)

Time: Baseline up to 12 months

Description: Length of time provider spends with the patient. This will be compared between the intervention group and control group.

Measure: Visit Time with provider

Time: Enrollment visit (baseline)

Description: Length of time between patient check-in and check-out. This will be compared between the intervention group and control group.

Measure: Total time in clinic

Time: Enrollment visit (baseline)

Description: This contains a 17-item questionnaire in which the participants select scores from 1-7 or does not apply. A number of 1 = not at all and a score of 7 = considered very true, and zero = not applicable.

Measure: Patient Motivation by the Treatment Self-Regulation Questionnaire scale (TSRQ)

Time: Baseline up to 12 months

Description: This is a 15-item questionnaire that assesses the quality of physician to patient communication completed by the patients. There are 5 answers to choose from; poor, fair, good, very good, and excellent. The Score range is 1-5, where 1 means negative perception of communication and 5 means positive perception of communication.

Measure: Satisfaction with CKD care based on Communication Assessment Tool (CAT)

Time: Baseline up to 12 months

Description: This is a 21-item questionnaire that is completed by the patients, and select from the the 4 choices: very strongly agree, strongly agree, agree, and neutral/disagree. Each answer is worth one point on a Likert scale with a higher score meaning more satisfied.

Measure: Satisfaction with CKD care based on Consultation Care Measure (CCM)

Time: Baseline up to 12 months

Description: During health coach phone calls, participants will be asked 37 questions about their perceptions of the health coach program, including how much their participation in CHECK-D helped participants change various behaviors. Participant responses will be used to examine various measures of reliability and validity during the analyses of data acquired though this survey.

Measure: Perceptions of health coaching for the intervention group

Time: Baseline up to 12 months

Description: The EMR will be reviewed to evaluate the patients medication refills for adherence.

Measure: Medication adherence from the electronic medical record (EMR)

Time: Baseline up to 12 months

Description: This is an 8-item scale regarding self-efficacy where each statement is rated on the level of agreement from 1-5. 1 is disagree and 5 is agree.

Measure: Self-efficacy for disease self-management based on The Perceived Kidney/Dialysis Self-Management Scale (PKDSMS)

Time: Baseline up to 12 months

Description: This is a 5-item survey about knowledge and behaviors regarding sodium in the diet.

Measure: Self-reported Blood Pressure-Related Behaviors Survey

Time: Baseline up to 12 months

Description: Provider adoption will be measured by the percentage of enrolled patients whose providers used the EDI with them during their visit. Data will be collected by EMR query and a 1-item question in the patient survey.

Measure: Provider Adoption based on EMR query and patient survey

Time: Baseline

Description: Provider fidelity will be measured by the percentage of enrolled patients in the intervention clinics whose providers entered 1-2 patient specific goals in the EDI. This will be collected through EMR query.

Measure: Provider Fidelity measured by EMR query

Time: Baseline

Description: Provider perception of usefulness will be measured by a survey of 2-3 questions about how useful they thought it was.

Measure: Provider Perception of Usefulness by provider survey

Time: Baseline up to 12 months

Description: Change in Serum Creatinine between baseline and 12-months

Measure: Change in serum creatinine

Time: Baseline, 12 months

Measure: Change in urine protein-creatinine ratio

Time: Baseline, 12 months

Measure: Change in estimated glomerular filtration rate (eGFR)

Time: Baseline, 12 months
3 Pharmacokinetics, Safety and Tolerability After Single Dose Administration of BI 764198 in Subjects With Moderate and Severe Renal Impairment in Comparison to Subjects With Normal Renal Function (a Mono-centric, Open-label Study With Matched-pair Design)

The main objective of this trial is to investigate the influence of moderate and severe renal impairment on the pharmacokinetics of a single dose of BI 764198 in comparison to a group of matched controls with normal renal function.

NCT04176536
Conditions
  1. Healthy
  2. Chronic Kidney Disease
Interventions
  1. Drug: BI 764198
MeSH:Kidney Diseases Renal Insufficiency, Chronic
HPO:Abnormality of the kidney Chronic kidney disease Nephropathy

Primary Outcomes

Measure: AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)

Time: Up to 96 hours

Measure: Cmax (maximum measured concentration of the analyte in plasma)

Time: Up to 96 hours

Secondary Outcomes

Measure: AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 the last quantifiable data point)

Time: Up to 96 hours
4 Single-Centre, Randomised, Double-Blind, 3-Period Cross-Over Study to Investigate Effects on QTcF Interval of Verinurad ER 24 mg or IR 40 mg in Combination With Allopurinol 300 mg, Compared to Matching Placebos In Healthy Volunteers

This study will be conducted to investigate the safety of verinurad in healthy volunteers in combination with allopurinol 300 mg, compared with placebo in particular its effect on electrocardiogram (ECG), with focus on the QT/QTc interval

NCT04256629
Conditions
  1. Healthy Volunteers (Intended Indication: Chronic Kidney Disease)
Interventions
  1. Drug: Verinurad
  2. Drug: Placebo
  3. Drug: Allopurinol
MeSH:Kidney Diseases Renal Insufficiency, Chronic
HPO:Abnormality of the kidney Chronic kidney disease Nephropathy

Primary Outcomes

Description: To assess the effect of a single dose of verinurad given as either a 24 mg ER8 formulation (therapeutic exposure) or a 40 mg IR formulation (supra-therapeutic exposure), both in combination with allopurinol 300 mg, on the QTcF interval compared to placebo using a concentration-QTcF interval analysis

Measure: Maximum observed plasma concentration (Cmax)

Time: Visit 2,3,4:- Day 1: Pre-dose, 0.5,1,1.5,2, 3, 4, 5, 6, 7, 8 and 12 hours post-dose; Day 2: 24 and 36 hours post-dose; Day 3: 48 hours post-dose

Description: To assess the effect of a single dose of verinurad given as either a 24 mg ER8 formulation (therapeutic exposure) or a 40 mg IR formulation (supra-therapeutic exposure), both in combination with allopurinol 300 mg, on the QTcF interval compared to placebo using a concentration-QTcF interval analysis

Measure: Baseline-corrected and placebo-adjusted QTcF interval (ΔΔQTcF)

Time: Screening; Visit 2,3,4:- Day -1, 1,2, 3; Follow up visit (7 to 10 days after the last dose)

Secondary Outcomes

Description: To investigate the effect of verinurad given either as a 24 mg ER8 formulation (therapeutic exposure) or a 40 mg IR formulation(supratherapeutic exposure), both in combination with allopurinol 300 mg

Measure: Baseline-corrected heart rate (ΔHR)

Time: Visit 2,3, and 4:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post dose

Description: To investigate the effect of verinurad given either as a 24 mg ER8 formulation (therapeutic exposure) or a 40 mg IR formulation (supratherapeutic exposure), both in combination with allopurinol 300 mg

Measure: Baseline-corrected and placebo-adjusted heart rate (ΔΔHR)

Time: Visit 2,3, and 4:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post dose

Description: To investigate the effect of verinurad given either as a 24 mg ER8 formulation (therapeutic exposure) or a 40 mg IR formulation (supratherapeutic exposure), both in combination with allopurinol 300 mg

Measure: Baseline-corrected RR interval (ΔRR interval)

Time: Visit 2,3, and 4:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post dose

Description: To investigate the effect of verinurad given either as a 24 mg ER8 formulation (therapeutic exposure) or a 40 mg IR formulation (supratherapeutic exposure), both in combination with allopurinol 300 mg

Measure: Baseline-corrected and placebo-adjusted RR interval (ΔΔRR interval)

Time: Visit 2,3, and 4:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post dose

Description: To investigate the effect of verinurad given either as a 24 mg ER8 formulation (therapeutic exposure) or a 40 mg IR formulation (supratherapeutic exposure), both in combination with allopurinol 300 mg

Measure: Baseline-corrected PR interval (ΔPR interval)

Time: Visit 2,3, and 4:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post dose

Description: To investigate the effect of verinurad given either as a 24 mg ER8 formulation (therapeutic exposure) or a 40 mg IR formulation (supratherapeutic exposure), both in combination with allopurinol 300 mg

Measure: Baseline-corrected and placebo-adjusted PR interval (ΔΔPR interval)

Time: Visit 2,3, and 4:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post dose

Description: To investigate the effect of verinurad given either as a 24 mg ER8 formulation (therapeutic exposure) or a 40 mg IR formulation (supratherapeutic exposure), both in combination with allopurinol 300 mg

Measure: Baseline-corrected and placebo-adjusted QRS interval (ΔQRS interval)

Time: Visit 2,3, and 4:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post dose

Description: To investigate the effect of verinurad given either as a 24 mg ER8 formulation (therapeutic exposure) or a 40 mg IR formulation (supratherapeutic exposure), both in combination with allopurinol 300 mg

Measure: Baseline-corrected and placebo-adjusted QRS interval (ΔΔQRS interval)

Time: Visit 2,3, and 4:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post dose

Description: To investigate the effect of verinurad given either as a 24 mg ER8 formulation (therapeutic exposure) or a 40 mg IR formulation (supratherapeutic exposure), both in combination with allopurinol 300 mg

Measure: Baseline-corrected QT interval (ΔQT interval)

Time: Visit 2,3, and 4:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post dose

Description: To investigate the effect of verinurad given either as a 24 mg ER8 formulation (therapeutic exposure) or a 40 mg IR formulation (supratherapeutic exposure), both in combination with allopurinol 300 mg

Measure: Baseline-corrected and placebo-adjusted QT interval (ΔΔQT interval)

Time: Visit 2,3, and 4:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post dose

Description: To investigate the effect of verinurad given either as a 24 mg ER8 formulation (therapeutic exposure) or a 40 mg IR formulation (supratherapeutic exposure), both in combination with allopurinol 300 mg

Measure: Baseline-corrected QTcF interval (ΔQTcF interval)

Time: Visit 2,3, and 4:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post dose

Description: To investigate the effect of verinurad given either as a 24 mg ER8 formulation (therapeutic exposure) or a 40 mg IR formulation (supratherapeutic exposure), both in combination with allopurinol 300 mg

Measure: Baseline-corrected and placebo-adjusted QTcF interval (ΔΔQTcF interval)

Time: Visit 2,3, and 4:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post dose

Description: To assess the pharmacokinetics (PK) of verinurad and its metabolites (M1 and M8) and allopurinol and its metabolite (oxypurinol) in healthy subjects

Measure: Area under plasma concentration-time curve from zero to infinity (AUC)

Time: Visit 2, 3 and 4:- Day 1: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, and 12 h post-dose; Day 2: 24 and 36 h post-dose; Day 3: 48 h post-dose

Description: To assess the PK of verinurad and its metabolites (M1 and M8) and allopurinol and its metabolite (oxypurinol) in healthy subjects.

Measure: Area under the plasma concentration-curve from time zero to time of last quantifiable concentration (AUC0-t)

Time: Visit 2,3, and 4:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post dose

Description: To assess the PK of verinurad and its metabolites (M1 and M8) and allopurinol and its metabolite (oxypurinol) in healthy subjects

Measure: Maximum observed plasma concentration (Cmax)

Time: Visit 2,3, and 4:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post dose

Description: To assess the PK of verinurad and its metabolites (M1 and M8) and allopurinol and its metabolite (oxypurinol) in healthy subjects

Measure: Time to reach maximum observed plasma concentration (tmax)

Time: Visit 2, 3 and 4:- Day 1: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, and 12 h post-dose; Day 2: 24 and 36 h post-dose; Day 3: 48 h post-dose

Description: To assess the PK of verinurad and its metabolites (M1 and M8) and allopurinol and its metabolite (oxypurinol) in healthy subjects

Measure: Time delay between drug administration and the first observed concentration in plasma (tlag)

Time: Visit 2, 3 and 4:- Day 1: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, and 12 h post-dose; Day 2: 24 and 36 h post-dose; Day 3: 48 h post-dose

Description: To assess the PK of verinurad and its metabolites (M1 and M8) and allopurinol and its metabolite (oxypurinol) in healthy subjects

Measure: Half-life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t½λz)

Time: Visit 2, 3 and 4:- Day 1: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, and 12 h post-dose; Day 2: 24 and 36 h post-dose; Day 3: 48 h post-dose

Description: To assess the PK of verinurad and its metabolites (M1 and M8) and allopurinol and its metabolite (oxypurinol) in healthy subjects

Measure: Time of last quantifiable plasma concentration (tlast)

Time: Visit 2, 3 and 4:- Day 1: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, and 12 h post-dose; Day 2: 24 and 36 h post-dose; Day 3: 48 h post-dose

Description: To assess the PK of verinurad and its metabolites (M1 and M8) and allopurinol and its metabolite (oxypurinol) in healthy subjects

Measure: Apparent total body clearance of drug from plasma after extravascular administration (parent drug only) [CL/F]

Time: Visit 2, 3 and 4:- Day 1: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, and 12 h post-dose; Day 2: 24 and 36 h post-dose; Day 3: 48 h post-dose

Description: To assess the PK of verinurad and its metabolites (M1 and M8) and allopurinol and its metabolite (oxypurinol) in healthy subjects

Measure: Apparent volume of distribution during the terminal phase after extravascular administration (parent drug only) [Vz/F]

Time: Visit 2, 3 and 4:- Day 1: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, and 12 h post-dose; Day 2: 24 and 36 h post-dose; Day 3: 48 h post-dose

Description: To assess the PK of verinurad and its metabolites (M1 and M8) and allopurinol and its metabolite (oxypurinol) in healthy subjects

Measure: Apparent volume of distribution at steady state (Vss/F)

Time: Visit 2, 3 and 4:- Day 1: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, and 12 h post-dose; Day 2: 24 and 36 h post-dose; Day 3: 48 h post-dose

Description: To assess the PK of verinurad and its metabolites (M1 and M8) and allopurinol and its metabolite (oxypurinol) in healthy subjects

Measure: Mean residence time of the unchanged drug in the systemic circulation from zero to infinity (MRT)

Time: Visit 2, 3 and 4:- Day 1: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, and 12 h post-dose; Day 2: 24 and 36 h post-dose; Day 3: 48 h post-dose

Description: To assess clinical chemistry/hematology/urinalysis as a variable of safety and tolerability of verinurad and allopurinol

Measure: Number of subjects with abnormal haematology, clinical chemistry and urinalysis

Time: Screening; Visit 2,3 and 4:- Day -1, Day 3: 48 h post-dose, Follow up period

Description: To assess vital signs as a variable of safety and tolerability of verinurad and allopurinol

Measure: Number of subjects with abnormal blood pressure and pulse rate

Time: Screening; Visit 2,3 and 4:- Day -1, Day 1: pre-dose, 1 and 6 h post-dose; Day 2: 24 h post-dose; Day 3: 48 h post-dose, Follow up visit
5 The Impact of Coronavirus (COVID-19) Restrictions on Wellbeing, Quality of Life and Physical Activity in People With End-stage Renal Disease, Currently Dialysing In-centre Versus at Home in the UK and Their Experience of Telemedicine

To understand the impact of COVID-19 restrictions on the wellbeing, quality of life and physical activity of people with end-stage renal disease, currently dialysing in-centre versus at home in the UK and their experience of telemedicine.

NCT04422873
Conditions
  1. End Stage Renal Disease
  2. Sars-CoV2
MeSH:Kidney Diseases Kidney Failure, Chronic
HPO:Abnormality of the kidney Nephropathy

Primary Outcomes

Description: Participants will be asked during a qualitative interview about the effect of COVID-19 restrictions on their; well-being, quality of life and physical activity and sedentary behaviours

Measure: Qualitative assessment of the effect of COVID-19 restrictions on patients' well-being, quality of life and physical activity and sedentary behaviours

Time: Day 1

Secondary Outcomes

Description: Participants will be asked during a qualitative interview about their perceptions and experiences of telemedicine

Measure: Thematic analysis of qualitative interview exploring patients' experiences of telemedicine during the COVID-19 restrictions in the UK

Time: Day 1
6 Online, Home-based, Aerobic Training Program Among Adolescents With Chronic Diseases During COVID-19 Pandemic: A Randomized Controlled Trial

Data show that the coronavirus disease 2019 (COVID-19) symptoms can be severe in 4% and 3% of the adolescents aged 11-15 years and ≥ 16 years, respectively. In addition, the prevalence of chronic diseases among adolescents has increased in the last years. About 20% of the adolescents have some chronic disease, resulting in increased morbidity and mortality. In march, 2020, the quarantine was officially implemented in Sao Paulo, while elective medical appointments for adolescents with chronic disease were temporarily suspended. To mitigate the deleterious effect of the social isolation on physical and mental health among these patients, this study aims to test the effects of an online, home-based, exercise training program.

NCT04458246
Conditions
  1. Chronic Disease
  2. Chronic Diseases in Adolescence
  3. Chronic Disease of Immune System
  4. Chronic Kidney Diseases
Interventions
  1. Other: Exercise training group
MeSH:Kidney Diseases Renal Insufficiency, Chronic Immune System Diseases Chronic Disease
HPO:Abnormality of the kidney Chronic kidney disease Nephropathy

Primary Outcomes

Description: Semi structured interview

Measure: Safety and efficacy of a home-based exercise training program

Time: From baseline to 3 months of follow-up

Secondary Outcomes

Description: Semi structured interview

Measure: Patients perceptions during social isolation

Time: From baseline to 3 months of follow-up

Description: Quality of life will be assessed by means of Pediatric Quality of Life inventory (PedsQLTM 4.0)

Measure: Adolescents quality of life

Time: From baseline to 3 months of follow-up

Description: Will be assessed by means of a visual analog scale (from 0 - no disease activity) to 10 - maximum disease activity).

Measure: Disease activity

Time: From baseline to 3 months of follow-up

Description: Will be assessed using the visual analog scale from 0 (very good condition) to 10 (very poor condition).

Measure: Disease overall assessment

Time: From baseline to 3 months of follow-up

Description: Will be assessed by means of Strengths & Difficulties Questionnaires

Measure: Strengths and difficulties

Time: From baseline to 3 months of follow-up
7 Global Assessment of Acute and Chronic Kidney Disease Incidence and Outcomes in Patients With COVID-19 Infection

The coronavirus (COVID-19) pandemic has created a significant strain on health care resources across the world for managing critically ill patients. Emerging reports from China, South Korea and Italy have reported varying incidence of acute kidney (AKI) ranging from 5-15% with a mortality of 60-80% however there is no systematic assessment of the risk factors, recognition, course and outcomes in patients with and without kidney disease whose course is complicated by AKI1-4. Patients with underlying CKD, immunosuppressed patients with renal transplants and ESKD patients are at high risk for COVID-19 infection and there is limited information on the effect of COVID-19 on the course and outcomes of these patients. The requirement for renal support including IHD, CRRT and sorbent based therapies has been variable and has contributed to the intense pressure on the nephrology and critical care providers for delivering these therapies. As the COVID-19 pandemic expands in the USA and abroad, there is an intense need to understand the epidemiology of the disease and the resources needed for renal support to inform clinical management and public health interventions. In this study, the investigators aim to investigate health care facilities across the world (hospital wards, ICU, outpatient clinics, nursing homes, healthcare centers) to draw a global picture of incidence, risk factors, resources available for treatment and prognosis of acute and chronic kidney disease in patient with COVID 19 confirmed infection. The aim is to identify trends in patients with acute and chronic kidney disease, determine its incidence, treatment and outcomes in different settings across the world. This information will be used to develop and implement educational tools and resources to prevent deaths from AKI and progression of CKD in this and following pandemics.

NCT04491227
Conditions
  1. Covid19
  2. AKI
  3. CKD
  4. ESRD
  5. Transplant;Failure,Kidney
MeSH:Kidney Diseases Renal Insufficiency, Chronic Renal Insufficiency
HPO:Abnormality of the kidney Chronic kidney disease Nephropathy Renal insufficiency

Primary Outcomes

Description: Meeting of at least one of the modified KDIGO Criteria Increase or decrease in serum creatinine >0.3 mg/dl from reference in 48 hours Increase or decrease in serum creatinine > 50% from reference in 7 days Urine output < 400 ml/day

Measure: AKI incidence

Time: from hospital admission through hospital discharge upto 24 weeks

Description: initiation of intermittent hemodialysis, continuous hemodialysis or peritoneal dialysis during the hospital stay

Measure: Dialysis requirement

Time: through study completion upto 1 year from enrollment

Description: Deaths during primary hospitalization

Measure: hospital mortality

Time: through study completion within 1 year

Secondary Outcomes

Description: C-Complete: SCr < 0.3 mg/dL from reference P-Partial: Requires no dialysis but not complete recovery N-No recovery: Dialysis dependent C-Complete: SCr < 0.3 mg/dL from reference P-Partial: Requires no dialysis but not complete recovery N-No recovery: Dialysis dependent Percentage of patinets with renal functioanl recovery based on serum creatinien levels classfied as C-Complete: SCr < 0.3 mg/dL from reference P-Partial: Requires no dialysis but not complete recovery N-No recovery: Dialysis dependent

Measure: Renal functional recovery

Time: Assessed at at 3, 6 and 12 months from enrollment at hospital admission

Description: EQL5D scale and SH8 scales completed at 3, 6 and 12 months post enrollment

Measure: Functional status

Time: questionnaires to be completed at 3, 6 and 12 months from enrollment at hospital admission

Description: Number of days patient is in the hospital and ICU and is managed with ventilators, dialysis or other extracorporeal organ support e.g. ECMO during the hospital stay

Measure: Resource utilization

Time: Within 1 year of enrollment for primary hospitalization
8 A Phase 2b Randomised, Double-Blind, Placebo-Controlled, Multi-Centre, Dose-Ranging Study of AZD5718 in Participants With Proteinuric Chronic Kidney Disease

The purpose of the study is to evaluate the dose-response efficacy, safety, and pharmacokinetics (PK) of AZD5718 in participants with proteinuric chronic kidney disease.

NCT04492722
Conditions
  1. Chronic Kidney Disease
Interventions
  1. Drug: AZD5718
  2. Drug: Dapagliflozin 10 mg
  3. Drug: Placebo
MeSH:Kidney Diseases Renal Insufficiency, Chronic
HPO:Abnormality of the kidney Chronic kidney disease Nephropathy

Primary Outcomes

Description: To evaluate the dose response effect of AZD5718 on urine ACR at 20 weeks

Measure: Change from baseline in urine ACR to Week 20

Time: Week 1 to Week 20

Secondary Outcomes

Description: To evaluate the dose response effect of AZD5718 on urine ACR at 12 weeks

Measure: Change from baseline in urine ACR to Week 12

Time: Week 1 to Week 12

Description: To assess the safety and tolerability profile of AZD5718 treatment

Measure: Number of participants with adverse events and serious adverse events

Time: Screening to Week 24

Description: To evaluate the effect of AZD5718 on ambulatory blood pressure

Measure: Change from baseline in 24-hours mean systolic blood pressure to Week 12

Time: Week 1 to Week 12

Description: To assess the PK of AZD5718 after repeated oral dosing for 20 weeks

Measure: Plasma concentrations of AZD5718

Time: Week 2 to Week 20

Description: To assess the effect of AZD5718 on renal function

Measure: Change from baseline in estimated glomerular filtration rate (eGFR) to Week 12

Time: Week 1 to Week 12
9 COVID-19 Progression in End-Stage Kidney Disease

The purpose of this study is to collect genomic and clinical data among a cohort of hemodialysis patients and analyze the association between genetic markers and the development and severity of illness in response to SARS-CoV-2.

NCT04495907
Conditions
  1. SARS-CoV-2 Infection (Asymptomatic)
  2. SARS-CoV-2 Infection (Symptomatic)
MeSH:Infection Communicable Diseases Kidney Diseases Kidney Failure, Chronic
HPO:Abnormality of the kidney Nephropathy

Primary Outcomes

Measure: SARS-CoV-2 IgG

Time: An average of 6 months

Measure: Anti-SARS-CoV-2 IgG

Time: An average of 6 months
10 An Open-label, 3-Treatment, 3-Period, Fixed Sequence Study in Healthy Subjects to Assess the Pharmacokinetics of Verinurad and Allopurinol When Administered Alone, and in Combination With Single Doses of Cyclosporine or Rifampicin

This Phase 1 study aims to quantify the effects of cyclosporine, a broad transporter inhibitor, and rifampicin, an OATP1B1/3 inhibitor, on verinurad pharmacokinetics (PK). The study is conducted in accordance with Food and Drug Administration guidance on Clinical Drug Interaction Studies, 2020. Verinurad will be developed as a fixed combination since it will always be administered together with allopurinol.

NCT04532918
Conditions
  1. Chronic Kidney Disease
Interventions
  1. Drug: Verinurad
  2. Drug: Allopurinol
  3. Drug: Cyclosporine
  4. Drug: Rifampicin
MeSH:Kidney Diseases Renal Insufficiency, Chronic
HPO:Abnormality of the kidney Chronic kidney disease Nephropathy

Primary Outcomes

Description: Verinurad Cmax ratio of geometric mean of test treatment (verinurad+allopurinol with (cyclosporine or rifampicin), relative to reference treatment (verinurad+allopurinol alone) in each treatment period

Measure: Geometric mean ratio of maximum observed plasma peak concentration (Cmax) for verinurad

Time: Days 1 to 5: 30 minutes pre-dose and up to 96 hours post-dose

Description: Verinurad AUCinf ratio of geometric means of test treatment, relative to reference treatment in each treatment period

Measure: Geometric mean ratio of area under plasma concentration-time curve from time zero to infinity (AUCinf) for verinurad

Time: Days 1 to 5: 30 minutes pre-dose and up to 96 hours post-dose

Description: Verinurad AUClast ratio of geometric means of test treatment, relative to reference treatment in each treatment period

Measure: Geometric mean ratio of area under the plasma concentration-time curve from zero to time of last quantifiable concentration (AUClast) for verinurad

Time: Days 1 to 5: 30 minutes pre-dose and up to 96 hours post-dose

Secondary Outcomes

Description: Cmax ratio of geometric means of test treatment, relative to reference treatment in each treatment period

Measure: Geometric mean ratio of Cmax for verinurad metabolite: M1

Time: Days 1 to 5: 30 minutes pre-dose and up to 96 hours post-dose

Description: Cmax ratio of geometric means of test treatment, relative to reference treatment in each treatment period

Measure: Geometric mean ratio of Cmax for verinurad metabolite: M8

Time: Days 1 to 5: 30 minutes pre-dose and up to 96 hours post-dose

Description: AUCinf ratio of geometric means of test treatment, relative to reference treatment in each treatment period

Measure: Geometric mean ratio of AUCinf for verinurad metabolite: M1

Time: Days 1 to 5: 30 minutes pre-dose and up to 96 hours post-dose

Description: AUCinf ratio of geometric means of test treatment, relative to reference treatment in each treatment period

Measure: Geometric mean ratio of AUCinf for verinurad metabolite: M8

Time: Days 1 to 5: 30 minutes pre-dose and up to 96 hours post-dose

Description: AUClast ratio of geometric means of test treatment, relative to reference treatment in each treatment period

Measure: Geometric mean ratio of AUClast for verinurad metabolite: M1

Time: Days 1 to 5: 30 minutes pre-dose and up to 96 hours post-dose

Description: AUClast ratio of geometric means of test treatment, relative to reference treatment in each treatment period

Measure: Geometric mean ratio of AUClast for verinurad metabolite: M8

Time: Days 1 to 5: 30 minutes pre-dose and up to 96 hours post-dose

Description: Allopurinol Cmax ratio of geometric means of test treatment, relative to reference treatment in each treatment period

Measure: Geometric mean ratio of Cmax for allopurinol

Time: Days 1 to 5: 30 minutes pre-dose and up to 96 hours post-dose

Description: Allopurinol AUCinf ratio of geometric means of test treatment, relative to reference treatment in each treatment period

Measure: Geometric mean ratio of AUCinf for allopurinol

Time: Days 1 to 5: 30 minutes pre-dose and up to 96 hours post-dose

Description: Allopurinol AUClast ratio of geometric means of test treatment, relative to reference treatment in each treatment period

Measure: Geometric mean ratio of AUClast for allopurinol

Time: Days 1 to 5: 30 minutes pre-dose and up to 96 hours post-dose

Description: Oxypurinol Cmax ratio of geometric means of test treatment, relative to reference treatment in each treatment period

Measure: Geometric mean ratio of Cmax for oxypurinol

Time: Days 1 to 5: 30 minutes pre-dose and up to 96 hours post-dose

Description: Oxypurinol AUCinf ratio of geometric means of test treatment, relative to reference treatment in each treatment period

Measure: Geometric mean ratio of AUCinf for oxypurinol

Time: Days 1 to 5: 30 minutes pre-dose and up to 96 hours post-dose

Description: Oxypurinol AUClast ratio of geometric means of test treatment, relative to reference treatment in each treatment period

Measure: Geometric mean ratio of AUClast for oxypurinol

Time: Days 1 to 5: 30 minutes pre-dose and up to 96 hours post-dose

Description: Cmax of verinurad, M1, M8, allopurinol and oxypurinol when verinurad+allopurinol administered alone or in combination with cyclosporine or rifampicin in each treatment period

Measure: Cmax

Time: Days 1 to 5: 30 minutes pre-dose and up to 96 hours post-dose

Description: AUCinf of verinurad, M1, M8, allopurinol and oxypurinol when verinurad+allopurinol administered alone or in combination with cyclosporine or rifampicin in each treatment period

Measure: AUCinf

Time: Days 1 to 5: 30 minutes pre-dose and up to 96 hours post-dose

Description: AUClast of verinurad, M1, M8, allopurinol and oxypurinol when verinurad+allopurinol administered alone or in combination with cyclosporine or rifampicin in each treatment period

Measure: AUClast

Time: Days 1 to 5: 30 minutes pre-dose and up to 96 hours post-dose

Description: AUC(0-24) of verinurad, M1, M8, allopurinol and oxypurinol when verinurad+allopurinol administered alone or in combination with cyclosporine or rifampicin in each treatment period

Measure: Area under the concentration-time curve from time zero to 24 hours post-dose [AUC(0-24)]

Time: Days 1 to 5: 30 minutes pre-dose and up to 96 hours post-dose

Description: tmax of verinurad, M1, M8, allopurinol and oxypurinol when verinurad+allopurinol administered alone or in combination with cyclosporine or rifampicin in each treatment period

Measure: Time to reach peak or maximum observed concentration following drug (tmax)

Time: Days 1 to 5: 30 minutes pre-dose and up to 96 hours post-dose

Description: t½λz of verinurad, M1, M8, allopurinol and oxypurinol when verinurad+allopurinol administered alone or in combination with cyclosporine or rifampicin in each treatment period

Measure: Half-life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t½λz)

Time: Days 1 to 5: 30 minutes pre-dose and up to 96 hours post-dose

Description: λz of verinurad, M1, M8, allopurinol and oxypurinol when verinurad+allopurinol administered alone or in combination with cyclosporine or rifampicin in each treatment period

Measure: Terminal elimination rate constant (λz)

Time: Days 1 to 5: 30 minutes pre-dose and up to 96 hours post-dose

Description: CL/F of verinurad and allopurinol when verinurad+allopurinol administered alone or in combination with cyclosporine or rifampicin in each treatment period

Measure: Apparent total body clearance of drug from plasma after extravascular administration (CL/F)

Time: Days 1 to 5: 30 minutes pre-dose and up to 96 hours post-dose

Description: MRTinf of verinurad and allopurinol when verinurad+allopurinol administered alone or in combination with cyclosporine or rifampicin in each treatment period

Measure: Mean Residence Time of the unchanged drug in the systemic circulation (MRTinf)

Time: Days 1 to 5: 30 minutes pre-dose and up to 96 hours post-dose

Description: Vss/F of verinurad and allopurinol when verinurad+allopurinol administered alone or in combination with cyclosporine or rifampicin in each treatment period

Measure: Volume of distribution (apparent) at steady state following extravascular administration (Vss/F)

Time: Days 1 to 5: 30 minutes pre-dose and up to 96 hours post-dose

Description: Vz/F of verinurad and allopurinol when verinurad+allopurinol administered alone or in combination with cyclosporine or rifampicin in each treatment period

Measure: Apparent volume of distribution during the terminal phase after extravascular administration (Vz/F)

Time: Days 1 to 5: 30 minutes pre-dose and up to 96 hours post-dose

Description: MP ratio of Cmax for verinurad when verinurad+allopurinol administered alone or in combination with cyclosporine or rifampicin in each treatment period

Measure: Metabolite:Parent (MP) ratio of Cmax

Time: Days 1 to 5: 30 minutes pre-dose and up to 96 hours post-dose

Description: MP ratio of AUCinf for verinurad when verinurad+allopurinol administered alone or in combination with cyclosporine or rifampicin in each treatment period

Measure: MP ratio of AUCinf

Time: Days 1 to 5: 30 minutes pre-dose and up to 96 hours post-dose

Description: MP ratio of AUClast for verinurad when verinurad+allopurinol administered alone or in combination with cyclosporine or rifampicin in each treatment period

Measure: MP ratio of AUClast

Time: Days 1 to 5: 30 minutes pre-dose and up to 96 hours post-dose

Description: Observed values and change from baseline value in systolic and diastolic BP for subjects administered with verinurad and allopurinol in combination with cyclosporine or rifampicin

Measure: Number of subjects with abnormal blood pressure (BP)

Time: For approximately 9 weeks (from screening to follow-up)

Description: Observed values and change from baseline value in pulse rate for subjects administered with verinurad and allopurinol in combination with cyclosporine or rifampicin

Measure: Number of subjects with abnormal pulse rate

Time: For approximately 9 weeks (from screening to follow-up)

Description: Observed values and change from baseline value in temperature for subjects administered with verinurad and allopurinol in combination with cyclosporine or rifampicin

Measure: Number of subjects with abnormal temperature

Time: For approximately 9 weeks (from screening to follow-up)

Description: 12-lead resting ECG safety assessments if there are any abnormal findings for subjects administered with verinurad and allopurinol in combination with cyclosporine or rifampicin

Measure: Number of subjects with abnormal 12-lead electrocardiogram (ECG)

Time: At screening and post-treatment follow-up visit (7-14 day after last dose of verinurad)

Description: Any new or aggravated clinically relevant abnormal medical physical examination finding compared to the baseline assessment for subjects administered with verinurad and allopurinol in combination with cyclosporine or rifampicin

Measure: Number of subjects with abnormal physical examination

Time: For approximately 9 weeks (from screening to follow-up)

Description: Observed values and change from baseline value in hematology parameters for subjects administered with verinurad and allopurinol in combination with cyclosporine or rifampicin

Measure: Number of subjects with abnormal hematology parameters

Time: At screening, Day -1, Day 3 (Treatment Periods 1, 2 and 3) and post-treatment follow-up (7-14 days after last dose of verinurad)

Description: Observed values and change from baseline value in clinical chemistry parameters for subjects administered with verinurad and allopurinol in combination with cyclosporine or rifampicin

Measure: Number of subjects with abnormal clinical chemistry parameters

Time: At screening, Day -1 (Treatment Periods 1 and 3), Day 1, Day 2 and Day 3 (Treament Period 1), and post-treatment follow-up (7-14 days after last dose of verinurad)

Description: Observed values and change from baseline value in urinalysis parameters for subjects administered with verinurad and allopurinol in combination with cyclosporine or rifampicin

Measure: Number of subjects with abnormal urinalysis parameters

Time: At screening, Day -1 (Treatment Periods 1 and 3), Day 1, Day 2 and Day 3 (Treament Period 1), and post-treatment follow-up (7-14 days after last dose of verinurad)

Description: The number and percentage of subjects with AEs and the number of events for subjects administered with verinurad and allopurinol in combination with cyclosporine or rifampicin

Measure: Number of subjects with adverse events (AEs) and serious AEs

Time: For approximately 9 weeks (from screening to follow-up)
11 A Randomised, Single-dose, 3-period, 3-treatment, Crossover Study to Assess the Relative Bioavailability of 2 Different Formulations of Verinurad and Allopurinol in Healthy Subjects

This study is a single centre, randomised, open-label, single-dose, 3-period, 3-treatment, crossover study in healthy male and female subjects. This study is intended to assess the relative bioavailability between the ph3 (fixed dose combination) and ph2b (free combination) formulations of verinurad and allopurinol. For verinurad, both formulations have an extended release profile. For allopurinol, both formulations have an immediate release profile.

NCT04550234
Conditions
  1. Chronic Kidney Disease
Interventions
  1. Drug: Verinurad
  2. Drug: Allopurinol
MeSH:Kidney Diseases Renal Insufficiency, Chronic
HPO:Abnormality of the kidney Chronic kidney disease Nephropathy

Primary Outcomes

Description: Area under plasma concentration time curve from time zero to infinity (AUCinf) of verinurad, allopurinol and oxypurinol.

Measure: Evaluation of the relative bioavailability of verinurad, allopurinol and oxypurinol after dosing with the ph3 and ph2b formulations under fasted conditions by AUCinf

Time: Days 1 to 4: pre-dose and upto 72 hours post-dose

Description: Area under the plasma concentration time curve from time zero to time of last quantifiable concentration (AUClast) of verinurad, allopurinol and oxypurinol.

Measure: Evaluation of the relative bioavailability of verinurad, allopurinol and oxypurinol after dosing with the ph3 and ph2b formulations under fasted conditions by AUClast

Time: Days 1 to 4: pre-dose and upto 72 hours post-dose

Description: Maximum observed plasma (peak) drug concentration (Cmax) of verinurad, allopurinol and oxypurinol.

Measure: Evaluation of the relative bioavailability of verinurad, allopurinol and oxypurinol after dosing with the ph3 and ph2b formulations under fasted conditions by Cmax

Time: Days 1 to 4: pre-dose and upto 72 hours post-dose

Secondary Outcomes

Description: Area under plasma concentration time curve from time zero to infinity of verinurad, allopurinol and oxypurinol.

Measure: Evaluation of the relative bioavailability of verinurad, allopurinol and oxypurinol after dosing with the ph3 formulation under fed and fasted conditions by AUCinf

Time: Days 1 to 4: pre-dose and upto 72 hours post-dose

Description: Area under the plasma concentration time curve from time zero to time of last quantifiable concentration of verinurad, allopurinol and oxypurinol.

Measure: Evaluation of the relative bioavailability of verinurad, allopurinol and oxypurinol after dosing with the ph3 formulation under fed and fasted conditions by AUClast

Time: Days 1 to 4: pre-dose and upto 72 hours post-dose

Description: Maximum observed plasma (peak) drug concentration of verinurad, allopurinol and oxypurinol.

Measure: Evaluation of the relative bioavailability of verinurad, allopurinol and oxypurinol after dosing with the ph3 formulation under fed and fasted conditions by Cmax

Time: Days 1 to 4: pre-dose and upto 72 hours post-dose

Description: Area under plasma concentration time curve from time zero to infinity of verinurad, allopurinol and oxypurinol.

Measure: Assessment of the pharmacokinetic profiles of verinurad, allopurinol and oxypurinol when administered as the ph3 formulation under fed and fasted conditions and the ph2b formulation in the fasted state by AUCinf

Time: Days 1 to 4: pre-dose and upto 72 hours post-dose

Description: Area under the plasma concentration time curve from time zero to time of last quantifiable concentration of verinurad, allopurinol and oxypurinol.

Measure: Assessment of the pharmacokinetic profiles of verinurad, allopurinol and oxypurinol when administered as the ph3 formulation under fed and fasted conditions and the ph2b formulation in the fasted state by AUClast

Time: Days 1 to 4: pre-dose and upto 72 hours post-dose

Description: Maximum observed plasma (peak) drug concentration of verinurad, allopurinol and oxypurinol.

Measure: Assessment of the pharmacokinetic profiles of verinurad, allopurinol and oxypurinol when administered as the ph3 formulation under fed and fasted conditions and the ph2b formulation in the fasted state by Cmax

Time: Days 1 to 4: pre-dose and upto 72 hours post-dose

Description: Time to reach maximum observed plasma concentration following drug administration (tmax) of verinurad, allopurinol and oxypurinol.

Measure: Assessment of the pharmacokinetic profiles of verinurad, allopurinol and oxypurinol when administered as the ph3 formulation under fed and fasted conditions and the ph2b formulation in the fasted state by tmax

Time: Days 1 to 4: pre-dose and upto 72 hours post-dose

Description: Time delay between drug administration and the first observed concentration in plasma (tlag) of verinurad, allopurinol and oxypurinol.

Measure: Assessment of the pharmacokinetic profiles of verinurad, allopurinol and oxypurinol when administered as the ph3 formulation under fed and fasted conditions and the ph2b formulation in the fasted state by tlag

Time: Days 1 to 4: pre-dose and upto 72 hours post-dose

Description: Terminal elimination rate constant (λz) of verinurad, allopurinol and oxypurinol.

Measure: Assessment of the pharmacokinetic profiles of verinurad, allopurinol and oxypurinol when administered as the ph3 formulation under fed and fasted conditions and the ph2b formulation in the fasted state by λz

Time: Days 1 to 4: pre-dose and upto 72 hours post-dose

Description: Half life associated with terminal slope (λz) of a semi logarithmic concentration time curve (t½λz) of verinurad, allopurinol and oxypurinol.

Measure: Assessment of the pharmacokinetic profiles of verinurad, allopurinol and oxypurinol when administered as the ph3 formulation under fed and fasted conditions and the ph2b formulation in the fasted state by t½λz

Time: Days 1 to 4: pre-dose and upto 72 hours post-dose

Description: Apparent total body clearance of drug from plasms after extravascular administration (parent drug only) (CL/F) of verinurad, allopurinol and oxypurinol.

Measure: Assessment of the pharmacokinetic profiles of verinurad, allopurinol and oxypurinol when administered as the ph3 formulation under fed and fasted conditions and the ph2b formulation in the fasted state by CL/F

Time: Days 1 to 4: pre-dose and upto 72 hours post-dose

Description: Mean residence time of the unchanged drug in the systemic circulation from zero to infinity (MRTinf) of verinurad, allopurinol and oxypurinol.

Measure: Assessment of the pharmacokinetic profiles of verinurad, allopurinol and oxypurinol when administered as the ph3 formulation under fed and fasted conditions and the ph2b formulation in the fasted state by MRTinf

Time: Days 1 to 4: pre-dose and upto 72 hours post-dose

Description: Volume of distribution (apparent) at steady state following extravascular administration (Vss/F) of verinurad, allopurinol and oxypurinol.

Measure: Assessment of the pharmacokinetic profiles of verinurad, allopurinol and oxypurinol when administered as the ph3 formulation under fed and fasted conditions and the ph2b formulation in the fasted state by Vss/F

Time: Days 1 to 4: pre-dose and upto 72 hours post-dose

Description: Apparent volume of distribution during the terminal phase after extravascular administration (Vz/F) of verinurad, allopurinol and oxypurinol.

Measure: Assessment of the pharmacokinetic profiles of verinurad, allopurinol and oxypurinol when administered as the ph3 formulation under fed and fasted conditions and the ph2b formulation in the fasted state by Vz/F

Time: Days 1 to 4: pre-dose and upto 72 hours post-dose

Description: Assessment of the safety of single doses of verinurad and allopurinol.

Measure: Number of subjects with serious and non-serious adverse events

Time: From Screening (Days -28 to -2) to follow-up visit (7 to 14 days post final dose)

HPO Nodes


HP:0000077: Abnormality of the kidney
Genes 1719
WT1 SMARCAL1 SLC34A1 SDCCAG8 KCNJ1 MICOS13 INSR ELP1 IL17F AMMECR1 KCNAB2 NF1 STIL CASP10 KCNJ11 CC2D2A GPR35 MYLK TMEM138 DYNC2LI1 RAG2 SLC9A3R1 NSD1 CYP11B2 GNA11 KRT17 SF3B4 GLA WDR35 CC2D2A CCR1 CEP41 CCR6 NDUFS3 NUP133 ANOS1 PIK3CA MOCOS INS GBA CDK6 CFI FGFR3 TRNT XRCC4 CLCNKB BSCL2 PIEZO2 BCOR LMNB2 IFT43 PHYH SLX4 DICER1 INSR OCLN KMT2D NUP93 BBS4 ABCG8 BUB3 DHODH LRP5 AQP2 ATRX AKT3 SCARB2 ABCA12 GLA FANCI FGFR1 BRF1 RAI1 RAB18 FOXF1 EDNRB CLCN5 FLRT3 SLC25A11 EVC2 SI TBC1D20 DICER1 WNT4 DICER1 WT1 NUP133 PHC1 SOX9 FGF8 SALL4 LZTFL1 LTBP4 IFT80 UFD1 NDUFAF3 TDGF1 TMEM126B SDHD SEC61A1 LPIN2 IRF5 PTPRJ FANCE KITLG WIPF1 DLST COX6B1 HBB GANAB PKHD1 FGFR2 DCC COX14 ATP7B EP300 POU3F4 FREM1 SLC5A2 COL4A3 KIF14 EXTL3 DEAF1 COL4A3 PYGM WDPCP SLC34A1 HESX1 PIGP WAS ZFP57 IL23R FANCL CFH DIS3L2 PEX12 NCAPD3 DCHS1 ITGA3 SMAD4 MAFB NDUFV1 CFH PEX5 USP8 PCK1 TGM1 CFHR1 CREBBP PLG PKD1 PREPL IRAK1 ATRX ND6 AKT1 DNMT3A NSD2 C8ORF37 PEX2 MAD2L2 WDR19 PPP2R1A FOXP3 APC TRNL1 NODAL MSH6 DYNC2H1 KCNA1 PRDX1 PEX13 SMARCE1 ALPL NEK1 MEOX1 NDUFB3 PBX1 KCNJ10 CDKN1C PTEN RFWD3 PIGN PIGT KCNQ1OT1 COL5A2 NDUFAF3 H19 LEMD3 FGA PYGL MITF CHRM3 FAT4 TAPT1 MMUT DLL1 C3 KIF1B PALB2 NDUFS7 PDE6D SDHD CAMKMT WNT4 ACSL4 RTTN VHL ABCC8 KEAP1 SC5D SDHB STXBP1 STRADA EIF2AK3 NPHP3 MKKS FKRP ABCC6 TACO1 MCPH1 NEK8 SMARCD1 TRNF ALMS1 C1QA CDK5RAP2 TRPC6 CCDC28B ND3 PIGL C4A AVPR2 APOE AURKA AMER1 VHL FGFR3 CYP4F22 PRDM16 MRPS22 AP2S1 TP53 SLC7A9 ITGB4 COLEC11 PRKCSH APRT GDNF MBTPS2 RREB1 IFT140 TMEM237 CAD TSC2 NPHP3 PAH C1QBP WASHC5 SCN2A PC TMEM216 CYB561 TMCO1 MMUT PEX19 CFTR NDUFS1 ITGA2 NXN BBS12 LMOD1 MKS1 COL4A3 SOX10 NUP205 ZBTB16 COA8 SRY DYNC2I1 KCNJ11 FLT1 SMARCB1 RECQL4 PPP2R3C WT1 POR FAS MMACHC MBTPS2 DISP1 ROBO2 PDGFRL AXIN2 FLNA PTPN22 ASPM NRAS KYNU NAA10 TLR2 CENPF CCBE1 CDC73 WT1 GATA4 WDPCP SLC2A9 F8 FGFR2 TREX1 UBR1 GBA EBP KCTD1 TRIM28 GP1BB BBS12 SBDS SLC12A3 MAP11 REN TNXB RAD51 EMP2 NRIP1 ATN1 COL4A4 HNF1B PEX11B KLLN WT1 FH SLC17A5 ADAT3 C3 LIG4 TRNS1 IFT27 INPP5E FGFR2 EXT2 KYNU MAP2K2 UMOD APC CLCNKB ESCO2 CDC73 BRAF STAT4 PALB2 BBS7 PIGO HRAS SNAP29 TBX22 COL4A1 PLCD1 ADAMTS3 PIGL RAD51C CDH23 NDUFS4 FOXC2 LMNA SDHB SOX9 CDC42 GLMN SLC3A1 TBX1 CD96 DPH1 PTPN12 OFD1 RPGRIP1L SETD5 CCDC22 APPL1 COL14A1 IL2RG COQ8B ALOX12B ND4 WDR19 SLC6A17 PIGW SERPINF2 HELLPAR HNF1A NR0B1 DMRT3 PEX6 COPB2 NDUFB9 WDR19 ITGA8 HLA-DRB1 TRNV NPHP4 CD46 HPRT1 TP63 IFT172 CACNA1D WDR19 BUB1B RPL11 WNT4 CCN2 FAT4 SLC30A9 ANTXR1 SLC34A3 KDM6A CFHR3 OSGEP NUBPL SMS DYNC2LI1 PIGY TMEM231 LIMK1 GRHPR MINPP1 PDX1 LPIN1 NARS2 MAGI2 AFF4 LYZ NPHP4 AMMECR1 ARL6 ELN NADK2 NUP160 CEP55 IFT27 POLE H19 GBE1 TSC1 FUT8 ALDH18A1 HABP2 TBX1 SALL4 WDR4 SAA1 ADGRG2 UMOD NSDHL ZNF592 CEP135 KANSL1 NDUFV2 KNL1 ERCC8 PLG ROR2 HMGA2 GPC4 TRNQ XYLT2 NLRP3 KMT2A DSTYK ITGA8 FOXI1 CA2 WDR4 MYD88 LMAN1 LRP2 PEX1 DZIP1L GCM2 NDUFB10 SIX3 FRAS1 GP1BB CORIN AGGF1 RPGRIP1L NOD2 NUMA1 RERE UQCC2 H19-ICR MASP1 B9D1 CTU2 AGTR1 FANCB SLC1A1 FIBP PIK3CA UBR1 TRIM28 FOS PTPRO CCDC141 WT1 CPLANE1 PUS3 PAX2 CCDC141 PTPN22 RAI1 SPP1 ARMC5 IGF2 LEMD3 TRAF3IP1 HLA-DPB1 TMEM216 DHDDS MEN1 LMX1B TRNS1 CSPP1 TMEM216 TRNH PIGV HGD PEX14 IL12A WT1 ERCC4 DMXL2 FCGR2B REST SGPL1 MOCS2 CAV1 CC2D2A BBS10 SRP54 DHCR24 ABCC8 ARNT2 PCK2 BBS9 CD2AP DNASE1L3 NABP1 PDE6D HPSE2 AR ALG1 SKIV2L COA3 G6PC CFI PDGFRB INF2 ENPP1 NEUROD1 LZTFL1 ARL6 C1QC UMPS DNAJB11 CTNS BRCA2 CEP55 STXBP1 NELFA CD151 COX1 TBX1 TBL1XR1 CCND1 NSUN2 PAX2 TRRAP RPGRIP1L RAD51C LMNA BRCA1 ATP7A PRTN3 CSPP1 WDR35 ZEB2 HOXD13 TCTN2 SNAI2 SASS6 ALMS1 ETFDH ELN FGFR2 PLVAP PNPLA6 SULT2B1 F10 SON WDR19 NUP107 FAT4 LCAT KCNQ1OT1 FGF17 PIK3C2A CAV1 STRA6 IL17RA COQ6 CDKL5 NSD1 BUB1 YAP1 ARL6 ABCC6 COX2 WNT4 RET STOX1 COX20 HPRT1 USP9X INTU HDAC4 SPECC1L PPM1B IARS1 CTNS PEX3 MGME1 FAS CCND1 H19-ICR ARX ODC1 HNF1B PEX2 HSD11B2 SON NPHP1 RAG1 PRCC CEP120 SCO1 PHGDH G6PC3 SLC36A2 FGFR1 IFT80 SEC63 RBM8A MYMK GDF6 MAP3K1 SRCAP CPT2 MDM2 WWOX RAB3GAP2 HOGA1 MYH11 PET100 GLI3 PML SLC29A3 GP1BA WDR11 SCNN1B HSPG2 FBLN5 SCNN1B TMEM231 ZNF148 FRAS1 BLK SDHC SEMA3E FANCF IFT140 TBX3 KCNJ10 CHD7 CC2D2A SHH TCTN2 LMX1B CPT2 CEP290 ZIC2 MYO5B PGK1 PLEC KAT6A VDR CCND1 FANCG PPP3CA FUZ NIPBL YY1 IL7R ITGA2B FBN1 COQ7 CDKL5 NLRP3 KIAA0753 APOE ALDOB LETM1 INS FANCI PIGN GABBR2 APC2 EYA1 PIGA ACP5 ZAP70 TPRKB BUB1 MCM5 TMEM231 EPAS1 SPECC1L TFE3 SIX5 RPGRIP1L TRIM8 ASXL1 ETFA SF3B4 ALOXE3 PKD2 TRNN SMO TSC2 FGF10 BAX THOC6 TRAF3IP2 CLCN5 CEP290 ZNF423 DPF2 RPGRIP1L VPS33A NOTCH2 SLC4A4 DACT1 KLLN GANAB INPP5E WT1 PRKAR1A LMX1B CEP83 LRP4 WDR62 ANKS6 WAS OCRL CASP10 PIGT CA2 DHCR7 B9D2 RASGRP1 POGZ ANTXR1 LDLRAP1 IGF2 TMEM67 TMEM237 KIF7 EHMT1 KIAA0753 GNB1 MLH3 NOTCH3 DACT1 HNF4A INVS PQBP1 SLC3A1 FLCN ITGB4 VIPAS39 RARB CEP290 GRIP1 GLI2 WDR73 TMEM127 KAT6B BBIP1 AAGAB PACS1 PIK3CA TP53RK NDUFAF1 FBXL4 PEX13 COL1A1 FLNA HMBS TREX1 DNASE1 NOTCH2 MAX WT1 GPC3 VAC14 KIF1B USF3 DNAJC21 CCNQ USP9X BBIP1 NBN CWC27 PEX3 C1QB CHD7 CD109 EIF2AK3 ENG TKT MBTPS2 CLEC7A APC TALDO1 BSND RPL26 CIT TRIP11 USP8 WDR73 PGM3 FGFR1 FLNA SOX18 GNB1 PROKR2 KMT2D GATM FGFR3 GLI3 BCS1L HAAO TSC2 LRP4 POMT1 FAN1 B4GAT1 ARID1B PTEN STK11 CLCN5 SOX9 GPC3 MEFV OSTM1 CTLA4 BRIP1 INSL3 HOGA1 ATRX GATA3 MED25 TTC37 SALL4 YAP1 FXYD2 CHD7 MTRR PEX1 REN ND4 GPC3 MSH3 NCAPG2 STX3 TRIM32 CFH GRHPR TCF4 ALG8 BCOR TRNK NPHS1 CFI SLC7A7 HRAS SETBP1 IRF2BP2 RAI1 SLC35A2 SLC37A4 TFAP2A PTCH1 SEMA3E PIGQ CHST14 RPGRIP1 CEP120 XDH PDSS2 KCNH1 GALNT3 CLDN16 PEX10 ESCO2 NUP107 WT1 WRN DVL1 GCM2 COX8A BRAF NRAS POU6F2 RAD21 C4A MNX1 CEP290 GREB1L IL6 FLCN INF2 CTNNB1 SLC25A20 FANCA DSTYK KLHL7 RET WFS1 MST1 PEX12 DSE NDUFS6 NPHS2 SLC2A2 MET RAB23 GEMIN4 SCNN1A XRCC2 KISS1R TMEM67 WDR19 OFD1 FAM20A NTNG1 B2M CRTAP OCRL PIK3R2 WNT5A ALX4 AGPAT2 HSD17B4 DCLRE1C NPHP1 PMM2 GTF2IRD1 ND5 NDUFS8 FANCB FAS GPKOW SLC22A12 PIGY CEP57 FANCM LDLR ERCC6 CPT1A GPC4 CTLA4 MUC1 HPSE2 DIS3L2 OFD1 SDHB CLIP2 GCK COG6 COMT POR DCDC2 SFTPC XYLT1 STAT4 SLC4A1 GP1BA RMRP SLITRK6 GLIS3 SIX1 ERAP1 MAFB NDUFS2 ENPP1 BICC1 CFHR5 PDSS2 HIRA DKC1 TBCK AKT1 NPHP1 PAX6 SRY WFS1 GNAO1 TMEM107 PGAM2 SEC23B DYNC2I2 CHRM3 CYP24A1 KIF14 MDH2 GSN PLA2G2A TBC1D24 HLA-B CYTB WNT3 MKS1 TTC8 PROKR2 TRNL1 SLC6A20 PAX4 IQCB1 MEFV TMEM67 BCS1L PLAGL1 PRKCD HNF1A ADAMTS13 ND3 ARL3 CEP164 SLC12A1 STRA6 ND6 CLDN19 KMT2A COL4A1 RPS26 TTC21B ACTG2 AGXT LAMB2 CILK1 BBS10 MKS1 ARID2 SLC7A7 KCNQ1 EYA1 GCK ERBB3 ACTN4 IFT122 ADA2 FGFR2 SRC PMM2 RET TRNL1 HDAC8 LIPN THOC6 SDR9C7 PIK3CA DHCR7 RAB3GAP1 TREX1 IL17RC NPHP1 IFT172 NDUFB8 VHL TCTN3 RECQL4 PEX16 MITF SETBP1 KRAS TFAP2A CLCNKA ATP6V0A4 CPLANE1 RNU4ATAC ZIC3 B3GLCT RAI1 SALL1 CDKN1B F2 BBS5 PUF60 GREB1L DHX37 ND1 SDHD SLC26A4 TXNL4A HS6ST1 MSH2 ALDOB TRNE ND1 LAGE3 COQ2 HNF1B ATP1A1 LMNA COX10 MKKS THBD F5 LRIG2 TRIM37 HLA-DRB1 ALG9 FOXE1 FANCC H19-ICR SLC6A19 LIG4 TCTN3 COG1 MAP3K7 TBX15 H19 CFB MECP2 MFSD2A FANCB HNF4A PKD1 FANCD2 LARGE1 ADCY10 ZIC3 ADA PLCE1 CEP63 B9D1 BAZ1B TRNS2 PAFAH1B1 PCSK9 BCOR LRP5 CLCNKB FREM1 POMT2 DYNC2LI1 SMOC1 APRT COL4A5 SDHD ARX COA8 ITGB3 ACTG1 CLPB FLCN CAVIN1 PIGA FLNA ARID1B NPHP4 JAG1 FAM20A MMUT FAH ZNF423 STAT1 IFNG SDCCAG8 TBX18 YWHAE MED25 FGFR3 DYNC2I2 GLIS2 HYLS1 TACR3 TTC21B RNU4ATAC NPHS1 PIGL NDUFA6 PIK3R2 AIRE SF3B4 NPHP3 MEFV PIGV FH DPH1 SMC1A PIK3CA KAT6B CEP164 HMOX1 MEFV PLCD1 PUF60 DIS3L2 BTNL2 SPART PGM3 DUSP6 KANK2 NDUFA1 PLD1 TBC1D24 CHD7 BBS1 NDUFA11 ALG9 CASR FLII JAM3 SMARCAL1 PNKP NSMF BBS1 EP300 LEMD3 GLI3 EXT2 TSC1 ARL6IP6 SERPINH1 AMMECR1 HIC1 C8ORF37 FOXF1 BAP1 NPHP1 GP1BB F8 GDF6 TRNK DYNC2I2 PEX7 GABRD ABCC6 AGPAT2 POU6F2 PEX10 WDR73 MARS1 CSPP1 FANCA ATRX CDC73 OFD1 CLDN19 KCNJ10 NUP133 SPINK5 SLX4 HPRT1 IFIH1 SNRPB PRKCD SETD2 RPS19 SCN1B FCGR2A LAGE3 SLC26A1 CTH FEZF1 TP63 CDC73 TMEM231 TTR PDX1 STS FANCL FGF20 SOX17 GNAS DDX59 STAT5B ND2 KLF11 ARX OCRL MAP3K7 COG7 PEX7 SIX5 APOA1 IL12A-AS1 FOXH1 CASR PORCN STAT3 KIF14 COL4A4 FGF8 DLC1 CTNNB1 TRNT1 IFT43 CDK4 FKTN ITGA6 AKT1 SOX11 PRKCSH DDX59 CLCN5 KLRC4 TRIP13 PIEZO2 EVC CRB2 PEX6 TELO2 AGXT LRIG2 IFT172 DNA2 HLA-B DCHS1 FIBP NOD2 CEP290 HPRT1 SHANK3 SCO2 NDUFS2 NDUFB11 SLC25A22 VPS33A HSPA9 ADCY10 TP53 FLI1 NF1 CD46 GPC4 LIPT2 TIMMDC1 NDUFAF8 RAD21 BRCA2 GAS1 TMEM70 FASLG COX3 FANCB STRADA FAM20C ROR2 SDHA SNRPB MCTP2 PIGN ARVCF KIAA0586 INVS OPLAH TGIF1 FOXRED1 PTPN11 IQSEC2 SKI SDHC VPS33B MAPKBP1 MKKS NDUFAF4 CEP290 CISD2 B3GLCT AQP2 ZAP70 UBE2T BNC2 NPM1 SMC1A PEX1 AVPR2 PPARG STAG1 TRIM32 CCND2 TTC21B RBM10 EFEMP2 PRODH PORCN FLCN MYH9 FREM2 PTPN22 RBM10 PREPL PHEX RET GSN RFC2 IQCB1 OGG1 DCC RAF1 TSC1 CCNQ NDUFAF3 FOXP1 SOX10 EYA1 ANOS1 ERCC4 PTPN11 BBS2 VAMP7 CASR JMJD1C VANGL1 GRIA3 HBB MAFB NLRP3 PKD2 OSGEP FLNA TRIP13 SIX1 CACNA1S CENPJ PAX1 CDKN1B NAA10 TMEM126B ND5 NFIA SDHB BUB1B CLDN10 ATP6V1B1 EPG5 EHMT1 BMPER SOX4 ELP1 NR5A1 MKKS YY1AP1 NDUFAF2 LMNB2 HNF1A ARID1A RNF139 TCTN3 BRAF AIP TMEM67 POLR3A CPT2 TRNW TBX1 SPRY2 CCBE1 CPT1A HNF4A PPP1R15B SLC4A1 TRAF3IP1 CEP290 TNXB TMEM67 SEC24C BSCL2 DYNC2H1 NEUROD2 CDKN1C ANKLE2 BMP4 MAX TMEM107 SPRY4 PRMT7 COL7A1 TPRKB GPC3 PGAP2 ALG8 TTC8 PAX2 RSPO2 FANCE SHANK3 NPHP3 NDUFAF5 TMEM237 NOTCH2 TMEM67 SMARCC2 SDHAF2 PEX19 CD81 CHST14 RFWD3 PGK1 WDR35 CTNS ZFPM2 SURF1 LHX1 TMEM127 CDON NIPBL HNF4A CHD4 PHYH ACE ENPP1 RRM2B SCARB2 COQ2 DYNC2I1 NPHP1 APOB PEX5 ACVRL1 INTS1 FLCN GDF3 FH IL17RD SLC34A1 HNF1B PEX26 TRIP13 NUP85 TP53RK BRCA2 ITGA2B RIPK4 FIG4 VHL SMC3 B9D2 MAGED2 ANLN CASK XPNPEP3 TTC37 ZNF687 RERE TMEM67 TAF13 KRAS NIPAL4 MLXIPL HOXA13 RBBP8 KCNJ11 FREM2 SALL1 ATP6 NUP107 LAMB2 IKZF1 UBAC2 RARA LMX1B APC TMEM138 AGT SSR4 TCN2 MAP2K1 CHN1 DGKE VHL ND1 SMARCA4 APOL1 FIP1L1 MOCS1 NPHP3 HLA-DPA1 NEK8 SHPK ABCC8 TLR4 DVL3 RMND1 ADA DMP1 DYNC2H1 WNT3 TMEM216 MLH1 COPA PKHD1 FANCD2 BICC1 CPT2 ETFB FAM149B1 TBC1D8B SC5D GTF2I GDF2 BMPER FLNA MCC STXBP1 DNASE1L3 KCNE5 PYCR2 IL10 METTL5 SHH CRB2 SLC37A4 PTCH1 SH2B1 IGF2 CDC42 REST STAT3 TMEM260 AHI1 PRPS1 GNA11 GLI1 COL5A1 CACNA1D PTPN22 BBS4 TRNW ABCG5 AFF4 SDCCAG8 FN1 WT1 ADAMTSL1 FN1 HPS1 PROK2 WASHC5 SERPINA1 ITPR3 CEP152 MYO1E SLC12A3 PHF21A CYP27A1 SLC3A1 HNRNPU BUB1B FANCC ITGB3 DLL4 RAD54B SIK1 TBL2 SDHB TMEM216 DZIP1L RYR1 FLNB KYNU RBM8A IGF2 CEL SDCCAG8 MME ND2 CC2D2A PTH1R ARHGDIA KCTD1 GATA3 SEMA3A GP9 KCNJ5 ACTG2 LDHA TMEM231 CASR UMOD SUFU SARS2 HYMAI FLNA FLNB HMGA2 KDM6A PGAP3 SCNN1G VHL MCFD2 ACTB PUF60 COL3A1 CD96 CIT
Protein Mutations 4
C282T C677T K55R Y93H

HPO

Alphabetical listing of all HPO terms. Navigate: Correlations   Clinical Trials


HPO Nodes


HP:0000077: Abnormality of the kidney
Genes 1719
WT1 SMARCAL1 SLC34A1 SDCCAG8 KCNJ1 MICOS13 INSR ELP1 IL17F AMMECR1 KCNAB2 NF1 STIL CASP10 KCNJ11 CC2D2A GPR35 MYLK TMEM138 DYNC2LI1 RAG2 SLC9A3R1 NSD1 CYP11B2 GNA11 KRT17 SF3B4 GLA WDR35 CC2D2A CCR1 CEP41 CCR6 NDUFS3 NUP133 ANOS1 PIK3CA MOCOS INS GBA CDK6 CFI FGFR3 TRNT XRCC4 CLCNKB BSCL2 PIEZO2 BCOR LMNB2 IFT43 PHYH SLX4 DICER1 INSR OCLN KMT2D NUP93 BBS4 ABCG8 BUB3 DHODH LRP5 AQP2 ATRX AKT3 SCARB2 ABCA12 GLA FANCI FGFR1 BRF1 RAI1 RAB18 FOXF1 EDNRB CLCN5 FLRT3 SLC25A11 EVC2 SI TBC1D20 DICER1 WNT4 DICER1 WT1 NUP133 PHC1 SOX9 FGF8 SALL4 LZTFL1 LTBP4 IFT80 UFD1 NDUFAF3 TDGF1 TMEM126B SDHD SEC61A1 LPIN2 IRF5 PTPRJ FANCE KITLG WIPF1 DLST COX6B1 HBB GANAB PKHD1 FGFR2 DCC COX14 ATP7B EP300 POU3F4 FREM1 SLC5A2 COL4A3 KIF14 EXTL3 DEAF1 COL4A3 PYGM WDPCP SLC34A1 HESX1 PIGP WAS ZFP57 IL23R FANCL CFH DIS3L2 PEX12 NCAPD3 DCHS1 ITGA3 SMAD4 MAFB NDUFV1 CFH PEX5 USP8 PCK1 TGM1 CFHR1 CREBBP PLG PKD1 PREPL IRAK1 ATRX ND6 AKT1 DNMT3A NSD2 C8ORF37 PEX2 MAD2L2 WDR19 PPP2R1A FOXP3 APC TRNL1 NODAL MSH6 DYNC2H1 KCNA1 PRDX1 PEX13 SMARCE1 ALPL NEK1 MEOX1 NDUFB3 PBX1 KCNJ10 CDKN1C PTEN RFWD3 PIGN PIGT KCNQ1OT1 COL5A2 NDUFAF3 H19 LEMD3 FGA PYGL MITF CHRM3 FAT4 TAPT1 MMUT DLL1 C3 KIF1B PALB2 NDUFS7 PDE6D SDHD CAMKMT WNT4 ACSL4 RTTN VHL ABCC8 KEAP1 SC5D SDHB STXBP1 STRADA EIF2AK3 NPHP3 MKKS FKRP ABCC6 TACO1 MCPH1 NEK8 SMARCD1 TRNF ALMS1 C1QA CDK5RAP2 TRPC6 CCDC28B ND3 PIGL C4A AVPR2 APOE AURKA AMER1 VHL FGFR3 CYP4F22 PRDM16 MRPS22 AP2S1 TP53 SLC7A9 ITGB4 COLEC11 PRKCSH APRT GDNF MBTPS2 RREB1 IFT140 TMEM237 CAD TSC2 NPHP3 PAH C1QBP WASHC5 SCN2A PC TMEM216 CYB561 TMCO1 MMUT PEX19 CFTR NDUFS1 ITGA2 NXN BBS12 LMOD1 MKS1 COL4A3 SOX10 NUP205 ZBTB16 COA8 SRY DYNC2I1 KCNJ11 FLT1 SMARCB1 RECQL4 PPP2R3C WT1 POR FAS MMACHC MBTPS2 DISP1 ROBO2 PDGFRL AXIN2 FLNA PTPN22 ASPM NRAS KYNU NAA10 TLR2 CENPF CCBE1 CDC73 WT1 GATA4 WDPCP SLC2A9 F8 FGFR2 TREX1 UBR1 GBA EBP KCTD1 TRIM28 GP1BB BBS12 SBDS SLC12A3 MAP11 REN TNXB RAD51 EMP2 NRIP1 ATN1 COL4A4 HNF1B PEX11B KLLN WT1 FH SLC17A5 ADAT3 C3 LIG4 TRNS1 IFT27 INPP5E FGFR2 EXT2 KYNU MAP2K2 UMOD APC CLCNKB ESCO2 CDC73 BRAF STAT4 PALB2 BBS7 PIGO HRAS SNAP29 TBX22 COL4A1 PLCD1 ADAMTS3 PIGL RAD51C CDH23 NDUFS4 FOXC2 LMNA SDHB SOX9 CDC42 GLMN SLC3A1 TBX1 CD96 DPH1 PTPN12 OFD1 RPGRIP1L SETD5 CCDC22 APPL1 COL14A1 IL2RG COQ8B ALOX12B ND4 WDR19 SLC6A17 PIGW SERPINF2 HELLPAR HNF1A NR0B1 DMRT3 PEX6 COPB2 NDUFB9 WDR19 ITGA8 HLA-DRB1 TRNV NPHP4 CD46 HPRT1 TP63 IFT172 CACNA1D WDR19 BUB1B RPL11 WNT4 CCN2 FAT4 SLC30A9 ANTXR1 SLC34A3 KDM6A CFHR3 OSGEP NUBPL SMS DYNC2LI1 PIGY TMEM231 LIMK1 GRHPR MINPP1 PDX1 LPIN1 NARS2 MAGI2 AFF4 LYZ NPHP4 AMMECR1 ARL6 ELN NADK2 NUP160 CEP55 IFT27 POLE H19 GBE1 TSC1 FUT8 ALDH18A1 HABP2 TBX1 SALL4 WDR4 SAA1 ADGRG2 UMOD NSDHL ZNF592 CEP135 KANSL1 NDUFV2 KNL1 ERCC8 PLG ROR2 HMGA2 GPC4 TRNQ XYLT2 NLRP3 KMT2A DSTYK ITGA8 FOXI1 CA2 WDR4 MYD88 LMAN1 LRP2 PEX1 DZIP1L GCM2 NDUFB10 SIX3 FRAS1 GP1BB CORIN AGGF1 RPGRIP1L NOD2 NUMA1 RERE UQCC2 H19-ICR MASP1 B9D1 CTU2 AGTR1 FANCB SLC1A1 FIBP PIK3CA UBR1 TRIM28 FOS PTPRO CCDC141 WT1 CPLANE1 PUS3 PAX2 CCDC141 PTPN22 RAI1 SPP1 ARMC5 IGF2 LEMD3 TRAF3IP1 HLA-DPB1 TMEM216 DHDDS MEN1 LMX1B TRNS1 CSPP1 TMEM216 TRNH PIGV HGD PEX14 IL12A WT1 ERCC4 DMXL2 FCGR2B REST SGPL1 MOCS2 CAV1 CC2D2A BBS10 SRP54 DHCR24 ABCC8 ARNT2 PCK2 BBS9 CD2AP DNASE1L3 NABP1 PDE6D HPSE2 AR ALG1 SKIV2L COA3 G6PC CFI PDGFRB INF2 ENPP1 NEUROD1 LZTFL1 ARL6 C1QC UMPS DNAJB11 CTNS BRCA2 CEP55 STXBP1 NELFA CD151 COX1 TBX1 TBL1XR1 CCND1 NSUN2 PAX2 TRRAP RPGRIP1L RAD51C LMNA BRCA1 ATP7A PRTN3 CSPP1 WDR35 ZEB2 HOXD13 TCTN2 SNAI2 SASS6 ALMS1 ETFDH ELN FGFR2 PLVAP PNPLA6 SULT2B1 F10 SON WDR19 NUP107 FAT4 LCAT KCNQ1OT1 FGF17 PIK3C2A CAV1 STRA6 IL17RA COQ6 CDKL5 NSD1 BUB1 YAP1 ARL6 ABCC6 COX2 WNT4 RET STOX1 COX20 HPRT1 USP9X INTU HDAC4 SPECC1L PPM1B IARS1 CTNS PEX3 MGME1 FAS CCND1 H19-ICR ARX ODC1 HNF1B PEX2 HSD11B2 SON NPHP1 RAG1 PRCC CEP120 SCO1 PHGDH G6PC3 SLC36A2 FGFR1 IFT80 SEC63 RBM8A MYMK GDF6 MAP3K1 SRCAP CPT2 MDM2 WWOX RAB3GAP2 HOGA1 MYH11 PET100 GLI3 PML SLC29A3 GP1BA WDR11 SCNN1B HSPG2 FBLN5 SCNN1B TMEM231 ZNF148 FRAS1 BLK SDHC SEMA3E FANCF IFT140 TBX3 KCNJ10 CHD7 CC2D2A SHH TCTN2 LMX1B CPT2 CEP290 ZIC2 MYO5B PGK1 PLEC KAT6A VDR CCND1 FANCG PPP3CA FUZ NIPBL YY1 IL7R ITGA2B FBN1 COQ7 CDKL5 NLRP3 KIAA0753 APOE ALDOB LETM1 INS FANCI PIGN GABBR2 APC2 EYA1 PIGA ACP5 ZAP70 TPRKB BUB1 MCM5 TMEM231 EPAS1 SPECC1L TFE3 SIX5 RPGRIP1L TRIM8 ASXL1 ETFA SF3B4 ALOXE3 PKD2 TRNN SMO TSC2 FGF10 BAX THOC6 TRAF3IP2 CLCN5 CEP290 ZNF423 DPF2 RPGRIP1L VPS33A NOTCH2 SLC4A4 DACT1 KLLN GANAB INPP5E WT1 PRKAR1A LMX1B CEP83 LRP4 WDR62 ANKS6 WAS OCRL CASP10 PIGT CA2 DHCR7 B9D2 RASGRP1 POGZ ANTXR1 LDLRAP1 IGF2 TMEM67 TMEM237 KIF7 EHMT1 KIAA0753 GNB1 MLH3 NOTCH3 DACT1 HNF4A INVS PQBP1 SLC3A1 FLCN ITGB4 VIPAS39 RARB CEP290 GRIP1 GLI2 WDR73 TMEM127 KAT6B BBIP1 AAGAB PACS1 PIK3CA TP53RK NDUFAF1 FBXL4 PEX13 COL1A1 FLNA HMBS TREX1 DNASE1 NOTCH2 MAX WT1 GPC3 VAC14 KIF1B USF3 DNAJC21 CCNQ USP9X BBIP1 NBN CWC27 PEX3 C1QB CHD7 CD109 EIF2AK3 ENG TKT MBTPS2 CLEC7A APC TALDO1 BSND RPL26 CIT TRIP11 USP8 WDR73 PGM3 FGFR1 FLNA SOX18 GNB1 PROKR2 KMT2D GATM FGFR3 GLI3 BCS1L HAAO TSC2 LRP4 POMT1 FAN1 B4GAT1 ARID1B PTEN STK11 CLCN5 SOX9 GPC3 MEFV OSTM1 CTLA4 BRIP1 INSL3 HOGA1 ATRX GATA3 MED25 TTC37 SALL4 YAP1 FXYD2 CHD7 MTRR PEX1 REN ND4 GPC3 MSH3 NCAPG2 STX3 TRIM32 CFH GRHPR TCF4 ALG8 BCOR TRNK NPHS1 CFI SLC7A7 HRAS SETBP1 IRF2BP2 RAI1 SLC35A2 SLC37A4 TFAP2A PTCH1 SEMA3E PIGQ CHST14 RPGRIP1 CEP120 XDH PDSS2 KCNH1 GALNT3 CLDN16 PEX10 ESCO2 NUP107 WT1 WRN DVL1 GCM2 COX8A BRAF NRAS POU6F2 RAD21 C4A MNX1 CEP290 GREB1L IL6 FLCN INF2 CTNNB1 SLC25A20 FANCA DSTYK KLHL7 RET WFS1 MST1 PEX12 DSE NDUFS6 NPHS2 SLC2A2 MET RAB23 GEMIN4 SCNN1A XRCC2 KISS1R TMEM67 WDR19 OFD1 FAM20A NTNG1 B2M CRTAP OCRL PIK3R2 WNT5A ALX4 AGPAT2 HSD17B4 DCLRE1C NPHP1 PMM2 GTF2IRD1 ND5 NDUFS8 FANCB FAS GPKOW SLC22A12 PIGY CEP57 FANCM LDLR ERCC6 CPT1A GPC4 CTLA4 MUC1 HPSE2 DIS3L2 OFD1 SDHB CLIP2 GCK COG6 COMT POR DCDC2 SFTPC XYLT1 STAT4 SLC4A1 GP1BA RMRP SLITRK6 GLIS3 SIX1 ERAP1 MAFB NDUFS2 ENPP1 BICC1 CFHR5 PDSS2 HIRA DKC1 TBCK AKT1 NPHP1 PAX6 SRY WFS1 GNAO1 TMEM107 PGAM2 SEC23B DYNC2I2 CHRM3 CYP24A1 KIF14 MDH2 GSN PLA2G2A TBC1D24 HLA-B CYTB WNT3 MKS1 TTC8 PROKR2 TRNL1 SLC6A20 PAX4 IQCB1 MEFV TMEM67 BCS1L PLAGL1 PRKCD HNF1A ADAMTS13 ND3 ARL3 CEP164 SLC12A1 STRA6 ND6 CLDN19 KMT2A COL4A1 RPS26 TTC21B ACTG2 AGXT LAMB2 CILK1 BBS10 MKS1 ARID2 SLC7A7 KCNQ1 EYA1 GCK ERBB3 ACTN4 IFT122 ADA2 FGFR2 SRC PMM2 RET TRNL1 HDAC8 LIPN THOC6 SDR9C7 PIK3CA DHCR7 RAB3GAP1 TREX1 IL17RC NPHP1 IFT172 NDUFB8 VHL TCTN3 RECQL4 PEX16 MITF SETBP1 KRAS TFAP2A CLCNKA ATP6V0A4 CPLANE1 RNU4ATAC ZIC3 B3GLCT RAI1 SALL1 CDKN1B F2 BBS5 PUF60 GREB1L DHX37 ND1 SDHD SLC26A4 TXNL4A HS6ST1 MSH2 ALDOB TRNE ND1 LAGE3 COQ2 HNF1B ATP1A1 LMNA COX10 MKKS THBD F5 LRIG2 TRIM37 HLA-DRB1 ALG9 FOXE1 FANCC H19-ICR SLC6A19 LIG4 TCTN3 COG1 MAP3K7 TBX15 H19 CFB MECP2 MFSD2A FANCB HNF4A PKD1 FANCD2 LARGE1 ADCY10 ZIC3 ADA PLCE1 CEP63 B9D1 BAZ1B TRNS2 PAFAH1B1 PCSK9 BCOR LRP5 CLCNKB FREM1 POMT2 DYNC2LI1 SMOC1 APRT COL4A5 SDHD ARX COA8 ITGB3 ACTG1 CLPB FLCN CAVIN1 PIGA FLNA ARID1B NPHP4 JAG1 FAM20A MMUT FAH ZNF423 STAT1 IFNG SDCCAG8 TBX18 YWHAE MED25 FGFR3 DYNC2I2 GLIS2 HYLS1 TACR3 TTC21B RNU4ATAC NPHS1 PIGL NDUFA6 PIK3R2 AIRE SF3B4 NPHP3 MEFV PIGV FH DPH1 SMC1A PIK3CA KAT6B CEP164 HMOX1 MEFV PLCD1 PUF60 DIS3L2 BTNL2 SPART PGM3 DUSP6 KANK2 NDUFA1 PLD1 TBC1D24 CHD7 BBS1 NDUFA11 ALG9 CASR FLII JAM3 SMARCAL1 PNKP NSMF BBS1 EP300 LEMD3 GLI3 EXT2 TSC1 ARL6IP6 SERPINH1 AMMECR1 HIC1 C8ORF37 FOXF1 BAP1 NPHP1 GP1BB F8 GDF6 TRNK DYNC2I2 PEX7 GABRD ABCC6 AGPAT2 POU6F2 PEX10 WDR73 MARS1 CSPP1 FANCA ATRX CDC73 OFD1 CLDN19 KCNJ10 NUP133 SPINK5 SLX4 HPRT1 IFIH1 SNRPB PRKCD SETD2 RPS19 SCN1B FCGR2A LAGE3 SLC26A1 CTH FEZF1 TP63 CDC73 TMEM231 TTR PDX1 STS FANCL FGF20 SOX17 GNAS DDX59 STAT5B ND2 KLF11 ARX OCRL MAP3K7 COG7 PEX7 SIX5 APOA1 IL12A-AS1 FOXH1 CASR PORCN STAT3 KIF14 COL4A4 FGF8 DLC1 CTNNB1 TRNT1 IFT43 CDK4 FKTN ITGA6 AKT1 SOX11 PRKCSH DDX59 CLCN5 KLRC4 TRIP13 PIEZO2 EVC CRB2 PEX6 TELO2 AGXT LRIG2 IFT172 DNA2 HLA-B DCHS1 FIBP NOD2 CEP290 HPRT1 SHANK3 SCO2 NDUFS2 NDUFB11 SLC25A22 VPS33A HSPA9 ADCY10 TP53 FLI1 NF1 CD46 GPC4 LIPT2 TIMMDC1 NDUFAF8 RAD21 BRCA2 GAS1 TMEM70 FASLG COX3 FANCB STRADA FAM20C ROR2 SDHA SNRPB MCTP2 PIGN ARVCF KIAA0586 INVS OPLAH TGIF1 FOXRED1 PTPN11 IQSEC2 SKI SDHC VPS33B MAPKBP1 MKKS NDUFAF4 CEP290 CISD2 B3GLCT AQP2 ZAP70 UBE2T BNC2 NPM1 SMC1A PEX1 AVPR2 PPARG STAG1 TRIM32 CCND2 TTC21B RBM10 EFEMP2 PRODH PORCN FLCN MYH9 FREM2 PTPN22 RBM10 PREPL PHEX RET GSN RFC2 IQCB1 OGG1 DCC RAF1 TSC1 CCNQ NDUFAF3 FOXP1 SOX10 EYA1 ANOS1 ERCC4 PTPN11 BBS2 VAMP7 CASR JMJD1C VANGL1 GRIA3 HBB MAFB NLRP3 PKD2 OSGEP FLNA TRIP13 SIX1 CACNA1S CENPJ PAX1 CDKN1B NAA10 TMEM126B ND5 NFIA SDHB BUB1B CLDN10 ATP6V1B1 EPG5 EHMT1 BMPER SOX4 ELP1 NR5A1 MKKS YY1AP1 NDUFAF2 LMNB2 HNF1A ARID1A RNF139 TCTN3 BRAF AIP TMEM67 POLR3A CPT2 TRNW TBX1 SPRY2 CCBE1 CPT1A HNF4A PPP1R15B SLC4A1 TRAF3IP1 CEP290 TNXB TMEM67 SEC24C BSCL2 DYNC2H1 NEUROD2 CDKN1C ANKLE2 BMP4 MAX TMEM107 SPRY4 PRMT7 COL7A1 TPRKB GPC3 PGAP2 ALG8 TTC8 PAX2 RSPO2 FANCE SHANK3 NPHP3 NDUFAF5 TMEM237 NOTCH2 TMEM67 SMARCC2 SDHAF2 PEX19 CD81 CHST14 RFWD3 PGK1 WDR35 CTNS ZFPM2 SURF1 LHX1 TMEM127 CDON NIPBL HNF4A CHD4 PHYH ACE ENPP1 RRM2B SCARB2 COQ2 DYNC2I1 NPHP1 APOB PEX5 ACVRL1 INTS1 FLCN GDF3 FH IL17RD SLC34A1 HNF1B PEX26 TRIP13 NUP85 TP53RK BRCA2 ITGA2B RIPK4 FIG4 VHL SMC3 B9D2 MAGED2 ANLN CASK XPNPEP3 TTC37 ZNF687 RERE TMEM67 TAF13 KRAS NIPAL4 MLXIPL HOXA13 RBBP8 KCNJ11 FREM2 SALL1 ATP6 NUP107 LAMB2 IKZF1 UBAC2 RARA LMX1B APC TMEM138 AGT SSR4 TCN2 MAP2K1 CHN1 DGKE VHL ND1 SMARCA4 APOL1 FIP1L1 MOCS1 NPHP3 HLA-DPA1 NEK8 SHPK ABCC8 TLR4 DVL3 RMND1 ADA DMP1 DYNC2H1 WNT3 TMEM216 MLH1 COPA PKHD1 FANCD2 BICC1 CPT2 ETFB FAM149B1 TBC1D8B SC5D GTF2I GDF2 BMPER FLNA MCC STXBP1 DNASE1L3 KCNE5 PYCR2 IL10 METTL5 SHH CRB2 SLC37A4 PTCH1 SH2B1 IGF2 CDC42 REST STAT3 TMEM260 AHI1 PRPS1 GNA11 GLI1 COL5A1 CACNA1D PTPN22 BBS4 TRNW ABCG5 AFF4 SDCCAG8 FN1 WT1 ADAMTSL1 FN1 HPS1 PROK2 WASHC5 SERPINA1 ITPR3 CEP152 MYO1E SLC12A3 PHF21A CYP27A1 SLC3A1 HNRNPU BUB1B FANCC ITGB3 DLL4 RAD54B SIK1 TBL2 SDHB TMEM216 DZIP1L RYR1 FLNB KYNU RBM8A IGF2 CEL SDCCAG8 MME ND2 CC2D2A PTH1R ARHGDIA KCTD1 GATA3 SEMA3A GP9 KCNJ5 ACTG2 LDHA TMEM231 CASR UMOD SUFU SARS2 HYMAI FLNA FLNB HMGA2 KDM6A PGAP3 SCNN1G VHL MCFD2 ACTB PUF60 COL3A1 CD96 CIT
Protein Mutations 4
C282T C677T K55R Y93H

Reports

Data processed on September 26, 2020.

An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

Drug Reports   MeSH Reports   HPO Reports  

Interventions

4,180 reports on interventions/drugs

MeSH

691 reports on MeSH terms

HPO

263 reports on HPO terms

All Terms

Alphabetical index of all Terms

Google Colab

Python example via Google Colab Notebook